Bio-Rad Laboratories (BIO) 10-Q 9 Aug 18 2018 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2018	Aug. 02, 2018
Entity Registrant Name	BIO-RAD LABORATORIES, INC.
Entity Central Index Key	12,208
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Document Type	10-Q
Document Period End Date	Jun. 30, 2018
Document Fiscal Year Focus	2,018
Document Fiscal Period Focus	Q2
Amendment Flag	false
Common Class A [Member]
Entity Common Stock, Shares Outstanding		24,735,427
Common Class B [Member]
Entity Common Stock, Shares Outstanding		5,099,623

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
ASSETS:
Cash and cash equivalents	$ 403,006	$ 383,824
Short-term investments	415,241	371,154
Restricted investments	5,560	5,560
Accounts receivable, net	404,091	464,847
Inventories:
Raw materials	118,999	113,925
Work in process	140,917	142,589
Finished goods	331,517	338,290
Total inventories	591,433	594,804
Other current assets	173,003	156,460
Total current assets	1,992,334	1,976,649
Property, plant and equipment, at cost	1,289,367	1,305,150
Less: accumulated depreciation and amortization	(799,118)	(811,654)
Property, plant and equipment, net	490,249	493,496
Goodwill, net	500,022	506,069
Purchased intangibles, net	158,035	174,113
Other investments	3,170,820	1,027,736
Other assets	74,763	94,949
Total assets	6,386,223	4,273,012
LIABILITIES AND STOCKHOLDERS' EQUITY:
Accounts payable, accrued payroll and employee benefits	261,721	306,814
Current maturities of long-term debt and notes payable	1,721	420
Income and other taxes payable	29,585	39,941
Other current liabilities	149,394	155,521
Total current liabilities	442,421	502,696
Long-term debt, net of current maturities	438,776	434,581
Deferred income taxes	686,906	222,209
Other long-term liabilities	179,174	183,276
Total liabilities	1,747,277	1,342,762
Stockholders' equity:
Additional paid-in capital	376,595	361,231
Retained earnings	4,281,275	1,830,439
Accumulated other comprehensive income	(18,710)	738,794
Total stockholders' equity	4,638,946	2,930,250
Total liabilities and stockholders' equity	6,386,223	4,273,012
Common Class A [Member]
Stockholders' equity:
Common stock	2	2
Common Class B [Member]
Stockholders' equity:
Common stock	1	1
Treasury Class A [Member]
Stockholders' equity:
Treasury Stock, Value	(128)	(128)
Treasury Class B [Member]
Stockholders' equity:
Treasury Stock, Value	$ (89)	$ (89)

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets Parenthetical - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Allowance for Doubtful Accounts Receivable, Current	$ 21,466	$ 25,549
Common Class A [Member]
Common Stock, Shares, Issued	24,736,009	24,679,127
Common Stock, Shares, Outstanding	24,735,427	24,678,545
Common Class B [Member]
Common Stock, Shares, Issued	5,100,540	5,107,674
Common Stock, Shares, Outstanding	5,099,623	5,106,757
Treasury Class A [Member]
Treasury Stock, Shares	582	582
Treasury Class B [Member]
Treasury Stock, Shares	917	917

Condensed Consolidated Statemen

Condensed Consolidated Statements of Income (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Net sales	$ 575,911	$ 504,666	$ 1,127,430	$ 1,004,717
Cost of goods sold	274,244	231,291	523,560	461,279
Gross profit	301,667	273,375	603,870	543,438
Selling, general and administrative expense	210,425	212,489	419,555	406,891
Research and Development Expense	47,450	62,587	96,877	112,039
Segment profit (loss)	43,792	(1,701)	87,438	24,508
Interest expense	5,977	6,045	11,759	11,361
Foreign exchange (gains) losses, net	(15)	2,516	1,239	4,305
Unrealized Gain on Securities	(286,398)	0	(1,102,332)	0
Nonoperating Income (Expense)	15,858	11,382	27,003	12,425
Income before income taxes	340,086	1,120	1,203,775	21,267
(Provision) benefit for income taxes	(72,043)	3,915	(278,958)	(3,819)
Net income attributable to Bio-Rad	$ 268,043	$ 5,035	$ 924,817	$ 17,448
Basic earnings per share:
Net income per share basic attributable to Bio-Rad	$ 8.99	$ 0.17	$ 31.03	$ 0.59
Weighted average common shares - basic	29,814	29,613	29,801	29,597
Diluted earnings per share:
Net income per share diluted attributable to Bio-Rad	$ 8.87	$ 0.17	$ 30.63	$ 0.58
Weighted average common shares - diluted	30,219	30,006	30,197	29,962

Condensed Consolidated Stateme5

Condensed Consolidated Statements of Comprehensive Income (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Net Income (Loss) Attributable to Parent	$ 268,043	$ 5,035	$ 924,817	$ 17,448
Foreign currency translation adjustments	(124,118)	41,679	(77,572)	60,522
Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Adjustment, Net of Tax, Portion Attributable to Parent	1,458	(1,938)	1,176	(2,053)
Net unrealized holding gains (losses) on available-for-sale investments net of tax expense	(135)	54,564	(1,851)	134,713
Total other comprehensive income (loss) net of tax	(122,795)	94,305	(78,247)	193,182
Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest	$ 145,248	$ 99,340	$ 846,570	$ 210,630

Condensed Consolidated Stateme6

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Cash flows from operating activities:
Cash received from customers	$ 1,160,904	$ 999,779
Cash paid to suppliers and employees	(1,007,565)	(968,719)
Interest paid, net	(11,277)	(10,865)
Income tax payments, net	(47,620)	(19,066)
Investment proceeds and miscellaneous receipts, net	18,354	13,197
Proceeds from (payments for) forward foreign exchange contracts, net	5,412	(8,029)
Net cash provided by operating activities	118,208	6,297
Cash flows from investing activities:
Capital expenditures	(53,897)	(64,951)
Proceeds from dispositions of property, plant and equipment	4,100	21
Proceeds from divestiture of a product line	6,919	0
Proceeds from (payments for) acquisitions	266
Payments for acquisitions and long-term investments		(73,573)
Payments for purchases of intangible assets	(3)	(3,920)
Payments for purchases of marketable securities and investments	(183,001)	(142,993)
Proceeds from Sale of Debt Securities, Available-for-sale	34,548
Proceeds from sales of marketable securities and investments		39,362
Proceeds from maturities of marketable securities and investments	88,410	98,379
Net cash used in investing activities	(102,658)	(147,675)
Cash flows from financing activities:
Net payments on line-of-credit arrangements and notes payable	0	(36)
Payments on long-term borrowings	(1,505)	(149)
Payments of contingent consideration	(1,270)	(3,105)
Proceeds from issuance of common stock for shared-based compensation	3,274	3,778
Payments for purchases of treasury stock	0	(883)
Net cash provided by (used in) financing activities	499	(395)
Effect of foreign exchange rate changes on cash	3,053	7,190
Net increase (decrease) in cash, cash equivalents, and restricted cash	19,102	(134,583)
Beginning Cash, Cash Equivalents, and Restricted Cash	384,983	457,171
Cash and cash equivalents	403,006	321,584
Restricted Cash, Current	105	561
Restricted Cash, Noncurrent	974	443
Ending Cash, Cash Equivalents, and Restricted Cash	$ 404,085	$ 322,588

1. Organization, Consolidation

1. Organization, Consolidation and Presentation of Financial Statements	6 Months Ended
	Jun. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization, Consolidation and Presentation of Financial Statements Disclosure	1. BASIS OF PRESENTATION AND USE OF ESTIMATES Basis of Presentation In this report, “Bio-Rad,” “we,” “us,” “the Company” and “our” refer to Bio-Rad Laboratories, Inc. and its subsidiaries. The accompanying unaudited condensed consolidated financial statements of Bio-Rad have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) and reflect all adjustments which are, in the opinion of management, necessary to fairly state the results of the interim periods presented. All such adjustments are of a normal recurring nature. Results for the interim period are not necessarily indicative of the results for the entire year. The condensed consolidated balance sheet at December 31, 2017 has been derived from the audited consolidated financial statements at that date but does not include all of the information and footnotes required by GAAP for complete financial statements. The condensed consolidated financial statements should be read in conjunction with the notes to the consolidated financial statements contained in our Annual Report on Form 10-K for the year ended December 31, 2017 . We evaluate subsequent events and the evidence they provide about conditions existing at the date of the balance sheet as well as conditions that arose after the balance sheet date but through the date the financial statements are issued. The effects of conditions that existed at the balance sheet date are recognized in the financial statements. Events and conditions arising after the balance sheet date but before the financial statements are issued are evaluated to determine if disclosure is required to keep the financial statements from being misleading. To the extent such events and conditions exist, disclosures are made regarding the nature of events and the estimated financial effects of those events and conditions. Use of Estimates The preparation of the condensed consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingencies at the date of the financial statements as well as the reported amounts of revenues and expenses during the reporting periods. Bio-Rad bases its estimates on historical experience and on various other market-specific and other relevant assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates. Revenue Recognition On January 1, 2018, the Company adopted Accounting Standards Codification ("ASC") 606, "Revenue from Contracts with Customers," using the modified retrospective method applied to those contracts which were not completed as of January 1, 2018. Results for reporting periods beginning after January 1, 2018 are presented under ASC 606, while prior period amounts are not adjusted and continue to be reported under prior revenue guidance ASC 605, "Revenue Recognition." We recorded a net reduction to opening retained earnings of $0.1 million as of January 1, 2018 due to the cumulative impact of adopting ASC 606 with the impact primarily related to a customer loyalty program in the United States for which the resulting non-cash consideration is treated as variable consideration under the new revenue recognition accounting standard. The impact to revenue as a result of applying ASC 606 as compared to ASC 605 for the six months ended June 30, 2018 was not significant. The Company recognizes revenue from operations through the sale of products, services, and rental of instruments. Revenue from contracts with customers is recognized upon transfer of control of promised products or services to customers in an amount that reflects the consideration we expect to receive in exchange for those products or services. We enter into contracts that can include various combinations of products and services, which are generally accounted for as distinct performance obligations. Revenue is recognized net of any taxes collected from customers (sales tax, value added tax, etc.), which are subsequently remitted to government authorities. Our contracts from customers often include promises to transfer multiple products and services to a customer. Determining whether products and services are considered distinct performance obligations that should be accounted for separately versus together may require significant judgment and may or may not impact the timing of revenue recognition. Revenue associated with equipment that requires factory installation is not recorded until installation is complete and customer acceptance, if required, has occurred. Certain equipment requires installation due to the fact that the instruments are being operated in a clinical/laboratory environment, and the installation services could result in modification of the equipment in order to ensure that the instruments are working according to specifications of the customer which are subject to validation tests upon completion of the installation. Accordingly, in these cases, the delivery of the equipment and the installation are separate performance obligations. The Company will recognize the transaction price allocated to the equipment only upon customer acceptance, as the transfer of control has occurred in relation to the equipment at that point in time as the customer has the ability to direct the use of and obtain substantially all of the remaining benefits from the asset. The transaction price allocated to the installation services is also recognized upon completion of the services because without the completion of the installation services and related customer acceptance the customer cannot receive any of the benefits of the service. At the time revenue is recognized, a provision is recognized for estimated product returns as this right is considered variable consideration. Accordingly, when product revenues are recognized, the transaction price is reduced to the estimated amount that we expect to receive in exchange for transferring control for those products. Service revenues on extended warranty contracts are recognized ratably over the life of the service agreement as a stand-ready performance obligation. In those instances where the timing of revenue recognition differs from the timing of invoicing, we have determined that our contracts generally do not include a significant financing component. The primary purpose of our invoicing terms is to provide customers with simple and predictable methods of purchasing our products and services, not to either provide or receive financing to or from our customers. We record contract liabilities when cash payments are received or due in advance of our performance. We do not disclose the value of unsatisfied performance obligations for contracts with an original expected length of one year or less and for contracts in which we recognize revenue at the amount to which we have the right to invoice for services performed. Our payment terms vary by the type and location of our customer, and the products and services offered. The term between invoicing and when payment is due is not significant. Reagent Rental Agreements Reagent rental agreements are a diagnostic industry sales method that provides use of an instrument and consumables (reagents) to a customer on a per test basis. These agreements may also include maintenance of the underlying instruments retained at customer locations as well as initial training. The Company has concluded that the use of the instrument and related maintenance services (collectively known as “lease elements”) are not within the guidance of ASC 606 but rather ASC 840 Leases. Accordingly, the Company first allocates the transaction price between the lease elements and the non-lease elements based on relative standalone selling prices. The determination of the transaction price requires judgment and requires consideration of any fixed/minimum payments as well as estimates of variable consideration. After determining what portion of the transaction price should be allocated to the lease elements, any fixed consideration would be considered the minimum lease payment to be amortized straight line over the lease term and any variable consideration would be contingent rent to be recognized monthly as earned. For the portion of the transaction price allocated to the non-lease elements, which are principally the reagents, the related revenue will be recognized at a point in time when control transfers. Generally, the terms of the arrangements result in the transfer of control upon either (i) when the consumables are delivered or (ii) when the consumables are consumed by the customer. Revenue allocated to the lease elements are approximately 5% of total revenue and are included as part of the Net sales in our Condensed Consolidated Statements of Income. Contract costs: We apply a practical expedient to expense costs as incurred for costs to obtain a contract when the amortization period would have been one year or less. These costs, recorded within Selling, general and administrative expense, include our internal sales force compensation programs and certain partner sales incentive programs, as we have determined that annual compensation is commensurate with annual selling activities. Disaggregation of Revenue: The following table presents our revenues disaggregated by geographic region based primarily on the location of the use of the product or service (in millions, unaudited): Three Months Ended Six Months Ended June 30, June 30, 2018 2017 2018 2017 Europe $ 197.2 $ 163.9 $ 396.8 $ 348.9 Pacific Rim 122.0 107.5 231.4 202.3 United States 221.6 202.5 431.5 389.8 Other (primarily Canada and Latin America) 35.1 30.8 67.7 63.7 Total Net sales $ 575.9 $ 504.7 $ 1,127.4 $ 1,004.7 The disaggregation of our revenue by industry segment sources is presented in our Segment Information footnote (see Note 10). Deferred revenues represent mostly unrecognized fees billed or collected for extended service arrangements. Deferred revenues are recognized as (or when) the Company performs under the contract which is generally over time during the term of the service contract. A majority of our deferred revenue balance is classified as current with an expected length of one year or less. The increase in our total deferred revenue balance from $36.7 million at December 31, 2017 to $41.4 million at June 30, 2018 is primarily driven by cash payments received or due in advance of satisfying our performance obligations, offset by $22.4 million of revenue recognized that were included in our deferred revenue balance as of December 31, 2017 . We warrant certain equipment against defects in design, materials and workmanship, generally for a period of one year. Upon revenue recognition of that equipment, we establish, as part of Cost of goods sold, a provision for the expected costs of such warranty based on historical experience, specific warranty terms and customer feedback. A review is performed on a quarterly basis to assess the adequacy of our warranty accrual. Components of the warranty accrual, included in Other current liabilities and Other long-term liabilities in the Condensed Consolidated Balance Sheets, were as follows (in millions): January 1, 2018 $ 18.7 Provision for warranty 14.9 Actual warranty costs (17.5 ) June 30, 2018 $ 16.1 Recent Accounting Pronouncements Adopted In February 2018, the FASB issued Accounting Standards Update No. ("ASU") 2018-03, "Technical Corrections and Improvements to Financial Instruments - Recognition and Measurement of Financial Assets and Financial Liabilities." ASU 2018-03 amends certain items in ASU 2016-01 (see below) such as equity securities without a readily determinable fair value. ASU 2018-03 clarifies that an entity that uses the measurement alternative for equity securities without readily determinable fair values can change its measurement approach to fair value and once made the election is irrevocable. If an entity measures equity securities without readily determinable fair values at fair value, it must record a cumulative-effect adjustment to Retained earnings as of the beginning of the fiscal year in which the guidance is adopted. We adopted ASU 2018-03 on January 1, 2018 and made an irrevocable election to account for our investment of the ordinary shares of Sartorius AG at fair value (see ASU 2016-01 below). In January 2016, the FASB issued ASU 2016-01, "Recognition and Measurement of Financial Assets and Financial Liabilities." Amendments under ASU 2016-01, among other items, require that all equity investments in unconsolidated entities (other than those accounted for using the equity method of accounting) will generally be measured at fair value through earnings. Changes in fair value for equity securities will no longer be reported in other comprehensive income. For equity investments without readily determinable fair values, the cost method is also eliminated. We adopted ASU 2016-01 on January 1, 2018 and record equity investments without readily determinable fair values at cost, less impairment, and plus or minus subsequent adjustments for observable price changes and were valued at $0.6 million as of June 30, 2018 . Changes in the basis of these equity investments are reported in current earnings. For equity securities that are affected by ASU 2016-01 and ASU 2018-03, see Note 2 to the condensed consolidated financial statements, which primarily consists of our investment in Sartorius AG. The impact of the adoption of ASU 2016-01 and ASU 2018-03 on January 1, 2018 was through a cumulative-effect adjustment of $864.5 million to Total stockholders' equity by increasing Retained earnings of $1,543.7 million and decreasing Accumulated other comprehensive income of $679.2 million , including increasing Deferred income taxes by $232.9 million and an increase in Other investments of $1,097.4 million in our Condensed Consolidated Balance Sheet. As a result of ASU 2016-01 and ASU 2018-03 for the three and six months ended June 30, 2018 , we recorded $286.4 million and $1,102.3 million , respectively, for the Change in fair market value of equity securities in the Condensed Consolidated Statement of Income that resulted in a deferred tax expense for the three and six months ended June 30, 2018 of $62.6 million and $243.8 million , respectively. In March 2017, the FASB issued ASU 2017-07, "Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost," which changed how we present the net periodic benefit cost of our defined benefit pension and/or other postretirement plans. We adopted ASU 2017-07 on January 1, 2018 and applied the practical expedient to estimate amounts for comparative purposes utilizing the information disclosed in Note 12 to the consolidated financial statements in our Form 10-K for the year ended December 31, 2017. The interest costs are recorded in Interest expense, and the other costs are recorded in Other (income) expense, net in the Condensed Consolidated Statements of Income. For the second quarter of 2017 for interest costs and other costs, we reclassified $0.076 million , $0.538 million , and $0.036 million from Costs of goods sold (COGS), Selling, general and administrative expense (SG&A) and Research and development expense (R&D), respectively, to Interest expense of $0.275 million and Other (income) expense, net of $0.375 million . For the first six months of 2017 for interest costs and other costs, we reclassified $0.152 million , $1.076 million , and $0.072 million from COGS, SG&A and R&D, respectively, to Interest expense of $0.550 million and Other (income) expense, net of $0.750 million . In November 2016, the FASB issued ASU 2016-18, "Restricted Cash," which required us to cease to present transfers between cash and cash equivalents and restricted cash and restricted cash equivalents in the statement of cash flows. We adopted ASU 2016-18 on January 1, 2018 and updated the Condensed Consolidated Statements of Cash Flows to incorporate restricted cash included in Other current assets and Other assets of $1.1 million as of June 30, 2018 and $1.0 million as of June 30, 2017 . In October 2016, the FASB issued ASU 2016-16, "Intra-Entity Transfers of Assets Other Than Inventory," which required immediate recognition of income tax consequences of intercompany asset transfers, other than inventory transfers. We adopted ASU 2016-16 on January 1, 2018 on a modified retrospective basis through a cumulative-effect adjustment by decreasing Retained earnings by $17.6 million , and decreasing Prepaid taxes by $22.8 million and increasing Deferred tax assets by $5.2 million that are both recorded in Other assets in our Condensed Consolidated Balance Sheet. In August 2016, FASB issued ASU 2016-15, "Classification of Certain Cash Receipts and Cash Payments" and adopted it on January 1, 2018, which did not have an impact to our statement of cash flows presentation. In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers ("ASC 606"), an updated standard on revenue recognition. The new standard provides enhancements to the quality and consistency of how revenue is reported under the principle that revenue should be recognized in an amount that reflects the consideration to which the Company expects to be entitled in exchange for the transfer of promised goods or services. We adopted ASC 606 as of January 1, 2018 using the cumulative effect transition method as more fully described above under the caption “Revenue Recognition.” Recent Accounting Pronouncements to be Adopted In June 2016, the FASB issued ASU 2016-13, "Measurement of Credit Losses on Financial Instruments." ASU 2016-13 will replace the current incurred loss approach with an expected loss model for instruments measured at amortized cost and require entities to record allowances for available-for-sale debt securities rather than reduce the carrying amount under the current other-than-temporary impairment model. ASU 2016-13 is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. Early adoption is permitted for all entities for annual periods beginning after December 15, 2018, and interim periods therein. We are currently evaluating the effect ASU 2016-13 will have on our consolidated financial statements.

2. Fair Value Measurements

2. Fair Value Measurements	6 Months Ended
	Jun. 30, 2018
Fair Value Disclosures [Abstract]
Fair Value Measurements	FAIR VALUE MEASUREMENTS We determine the fair value of an asset or liability based on the assumptions that market participants would use in pricing the asset or liability in an orderly transaction between market participants at the measurement date. The identification of market participant assumptions provides a basis for determining what inputs are to be used for pricing each asset or liability. A fair value hierarchy has been established which gives precedence to fair value measurements calculated using observable inputs over those using unobservable inputs. This hierarchy prioritizes the inputs into three broad levels as follows: • Level 1: Quoted prices in active markets for identical instruments • Level 2: Other significant observable inputs (including quoted prices in active markets for similar instruments) • Level 3: Significant unobservable inputs (including assumptions in determining the fair value of certain investments) Financial assets and liabilities carried at fair value and measured on a recurring basis as of June 30, 2018 are classified in the hierarchy as follows (in millions): Level 1 Level 2 Level 3 Total Financial Assets Carried at Fair Value: Cash equivalents: Commercial paper $ — $ 68.4 $ — $ 68.4 Time deposits 25.7 10.0 — 35.7 Money market funds 30.2 — — 30.2 Foreign government obligations — 1.8 — 1.8 U.S. government sponsored agencies — 6.0 — 6.0 Total cash equivalents (a) 55.9 86.2 — 142.1 Restricted investment 5.6 — — 5.6 Equity securities (b) 3,196.6 — — 3,196.6 Available-for-sale investments: Corporate debt securities — 223.6 — 223.6 U.S. government sponsored agencies — 66.0 — 66.0 Foreign government obligations — 2.6 — 2.6 Municipal obligations — 15.6 — 15.6 Asset-backed securities — 62.9 — 62.9 Total available-for-sale investments (c) — 370.7 — 370.7 Forward foreign exchange contracts (d) — 0.6 — 0.6 Total financial assets carried at fair value $ 3,258.1 $ 457.5 $ — $ 3,715.6 Financial Liabilities Carried at Fair Value: Forward foreign exchange contracts (e) $ — $ 1.0 $ — $ 1.0 Contingent consideration (f) — — 13.0 13.0 Total financial liabilities carried at fair value $ — $ 1.0 $ 13.0 $ 14.0 As of first quarter 2018, our equity securities are no longer reported as Available-for-sale investments due to the implementation of ASU 2016-01. Changes in fair value of equity securities are now reported on the Condensed Consolidated Statements of Income rather than Other Comprehensive Income (see Note 1). Financial assets and liabilities carried at fair value and measured on a recurring basis as of December 31, 2017 are classified in the hierarchy as follows (in millions): Level 1 Level 2 Level 3 Total Financial Assets Carried at Fair Value: Cash equivalents: Commercial paper $ — $ 36.0 $ — $ 36.0 Time deposits 43.7 10.0 — 53.7 U.S. government sponsored agencies — 11.2 — 11.2 Money market funds 3.4 — — 3.4 Total cash equivalents (a) 47.1 57.2 — 104.3 Restricted investment 5.6 — — 5.6 Available-for-sale investments: Corporate debt securities — 185.7 — 185.7 U.S. government sponsored agencies — 67.6 — 67.6 Foreign government obligations — 3.4 — 3.4 Brokered certificates of deposit — 0.7 — 0.7 Municipal obligations — 15.0 — 15.0 Marketable equity securities 973.4 — — 973.4 Asset-backed securities — 55.6 — 55.6 Total available-for-sale investments (c) 973.4 328.0 — 1,301.4 Forward foreign exchange contracts (d) — 0.5 — 0.5 Total financial assets carried at fair value $ 1,026.1 $ 385.7 $ — $ 1,411.8 Financial Liabilities Carried at Fair Value: Forward foreign exchange contracts (e) $ — $ 1.6 $ — $ 1.6 Contingent consideration (f) — — 16.7 16.7 Total financial liabilities carried at fair value $ — $ 1.6 $ 16.7 $ 18.3 (a) Cash equivalents are included in Cash and cash equivalents in the Condensed Consolidated Balance Sheets. (b) Equity securities are included in the following accounts in the Condensed Consolidated Balance Sheets (in millions): June 30, 2018 Short-term investments $ 44.7 Other investments 3,151.9 Total $ 3,196.6 The unrealized gains on our equity securities still held as of June 30, 2018 are $1,102.3 million and are primarily due to our investment in Sartorius AG and is recorded in our Condensed Consolidated Statements of Income due to the adoption of ASU 2016-01 (see Note 1). (c) Available-for-sale investments are included in the following accounts in the Condensed Consolidated Balance Sheets (in millions): June 30, 2018 December 31, 2017 Short-term investments $ 370.5 $ 371.2 Other investments 0.2 930.2 Total $ 370.7 $ 1,301.4 In accordance with our adoption of ASU 2016-01 January 1, 2018, our investment in Sartorius AG preferred shares, which was reported within marketable equity securities as Available-for-sale as of December 31, 2017 , is now reported as an Equity security as of June 30, 2018 (see Note 1 and footnote (b) above). (d) Forward foreign exchange contracts in an asset position are included in Other current assets in the Condensed Consolidated Balance Sheets. (e) Forward foreign exchange contracts in a liability position are included in Other current liabilities in the Condensed Consolidated Balance Sheets. (f) Contingent consideration liability is included in the following accounts in the Condensed Consolidated Balance Sheets (in millions): June 30, 2018 December 31, 2017 Other current liabilities $ 2.6 $ 2.7 Other long-term liabilities 10.4 14.0 Total $ 13.0 $ 16.7 During the first quarter of 2016, we recognized a contingent consideration liability upon our acquisition of a high performance analytical flow cytometer platform from Propel. At the acquisition date, the amount of contingent consideration was determined based on a probability-weighted income approach related to the achievement of sales milestones, ranging from 39% to 20% for the calendar years 2018 through 2020 . The sales milestones could potentially range from $0 to an unlimited amount. In the first quarter of 2018, we paid $1.3 million per the purchase agreement. Since 2016 we have decreased the cumulative valuation of the sales milestones by $8.5 million . The contingent consideration was accrued at its estimated fair value of $13.0 million as of June 30, 2018 . The following table provides a reconciliation of the Level 3 analytical flow cytometer platform contingent consideration liabilities measured at estimated fair value (in millions): January 1, 2018 $ 16.7 Analytical flow cytometer platform: Payment of sales milestone (1.3 ) Decrease in estimated fair value of contingent consideration included in Selling, general and administrative expense (2.4 ) June 30, 2018 $ 13.0 The following table provides quantitative information about Level 3 inputs for fair value measurement of our analytical flow cytometer platform contingent consideration liability as of June 30, 2018 . Significant increases or decreases in these inputs in isolation could result in a significantly lower or higher fair value measurement. Valuation Technique Unobservable Input Analytical flow cytometer platform Probability-weighted income approach Sales milestones: Discount rate 11.1 % Cost of debt 4.8 % To estimate the fair value of Level 2 debt securities as of June 30, 2018 and December 31, 2017 , our primary pricing provider uses Securities Evaluations as the primary pricing source. Our pricing process allows us to select a hierarchy of pricing sources for securities held. If Securities Evaluations does not price a Level 2 security that we hold, then the pricing provider will utilize our custodian supplied pricing as the secondary pricing source. For commercial paper as of June 30, 2018 and December 31, 2017 , pricing is determined by a straight-line calculation, starting with the purchase price on the date of purchase and increasing to par at maturity. Interest bearing certificates of deposit and commercial paper are priced at par. In the event that an additional lot of the same commercial paper issue has been purchased within the same account, then the price of all holdings of that issue in that account will be the price of the most recent lot purchased. Our pricing provider performs daily reasonableness testing of the Securities Evaluations prices. Price changes of 5% or greater are investigated and resolved. In addition, we perform a quarterly comparison of the Securities Evaluations prices to custodian reported prices. Price differences outside a tolerable variance of approximately 1% are investigated and resolved. Available-for-sale investments consist of the following (in millions): June 30, 2018 Amortized Cost Unrealized Gains Unrealized Losses Estimated Fair Value Short-term investments: Corporate debt securities $ 224.9 $ 0.1 $ (1.4 ) $ 223.6 Municipal obligations 15.7 — (0.1 ) 15.6 Asset-backed securities 63.1 — (0.4 ) 62.7 U.S. government sponsored agencies 67.2 — (1.2 ) 66.0 Foreign government obligations 2.6 — — 2.6 373.5 0.1 (3.1 ) 370.5 Long-term investments: Asset-backed securities 0.2 — — 0.2 0.2 — — 0.2 Total $ 373.7 $ 0.1 $ (3.1 ) $ 370.7 The following is a summary of the amortized cost and estimated fair value of our debt securities at June 30, 2018 by contractual maturity date (in millions): Amortized Cost Estimated Fair Value Mature in less than one year $ 156.7 $ 156.4 Mature in one to five years 170.9 169.3 Mature in more than five years 46.1 45.0 Total $ 373.7 $ 370.7 Available-for-sale investments consist of the following (in millions): December 31, 2017 Amortized Cost Unrealized Gains Unrealized Losses Estimated Fair Value Short-term investments: Corporate debt securities $ 185.9 $ 0.3 $ (0.5 ) $ 185.7 Brokered certificates of deposit 0.7 — — 0.7 Municipal obligations 15.1 — (0.1 ) 15.0 Asset-backed securities 55.6 — (0.2 ) 55.4 U.S. government sponsored agencies 68.3 — (0.7 ) 67.6 Foreign government obligations 3.4 — — 3.4 Marketable equity securities 34.4 9.0 — 43.4 363.4 9.3 (1.5 ) 371.2 Long-term investments: Marketable equity securities 54.5 875.5 — 930.0 Asset-backed securities 0.2 — — 0.2 54.7 875.5 — 930.2 Total $ 418.1 $ 884.8 $ (1.5 ) $ 1,301.4 The following is a summary of investments with gross unrealized losses and the associated fair value (in millions): June 30, 2018 December 31, 2017 Fair value of investments in a loss position 12 months or more $ 36.9 $ 43.9 Fair value of investments in a loss position less than 12 months $ 199.4 $ 168.7 Gross unrealized losses for investments in a loss position 12 months or more $ 0.9 $ 0.7 Gross unrealized losses for investments in a loss position less than 12 months $ 2.2 $ 0.8 The unrealized losses on these securities are due to a number of factors, including changes in interest rates, changes in economic conditions and changes in market outlook for various industries, among others. Because Bio-Rad has the ability and intent to hold these investments with unrealized losses until a recovery of fair value, or for a reasonable period of time sufficient for a forecasted recovery of fair value, which may be maturity, we do not consider these investments to be other-than-temporarily impaired at June 30, 2018 or at December 31, 2017 . As part of distributing our products, we regularly enter into intercompany transactions. We enter into forward foreign exchange contracts to manage foreign exchange risk of future movements in foreign exchange rates that affect foreign currency denominated intercompany receivables and payables. We do not use derivative financial instruments for speculative or trading purposes. We do not seek hedge accounting treatment for these contracts. As a result, these contracts, generally with maturity dates of 90 days or less and denominated primarily in currencies of industrial countries, are recorded at their fair value at each balance sheet date. The notional principal amounts provide one measure of the transaction volume outstanding as of June 30, 2018 and do not represent the amount of Bio-Rad's exposure to loss. The estimated fair value of these contracts was derived using the spot rates from Reuters on the last business day of the quarter and the points provided by counterparties. The resulting gains or losses offset exchange gains or losses on the related receivables and payables, both of which are included in Foreign currency exchange losses, net in the Condensed Consolidated Statements of Income. The following is a summary of our forward foreign exchange contracts (in millions): June 30, 2018 Contracts maturing in July through September 2018 to sell foreign currency: Notional value $ 37.8 Unrealized loss $ 0.1 Contracts maturing in July through September 2018 to purchase foreign currency: Notional value $ 327.6 Unrealized loss $ 0.5 The estimated fair value of financial instruments that are not recognized at fair value in the Condensed Consolidated Balance Sheets and are included in Other investments, are presented in the table below. Fair value has been determined using significant observable inputs, including quoted prices in active markets for similar instruments. Estimates are not necessarily indicative of the amounts that could be realized in a current market exchange as considerable judgment is required in interpreting market data used to develop estimates of fair value. The use of different market assumptions or estimation techniques could have a material effect on the estimated fair value. Other investments include financial instruments, the majority of which have fair value based on similar, actively traded stock adjusted for various discounts, including a discount for marketability. Long-term debt, excluding leases and current maturities, has an estimated fair value based on quoted market prices for the same or similar issues. The estimated fair value of the financial instruments discussed above and the level of the fair value hierarchy within which the fair value measurement is categorized are as follows (in millions): June 30, 2018 December 31, 2017 Carrying Amount Estimated Fair Value Fair Value Hierarchy Level Carrying Amount Estimated Fair Value Fair Value Hierarchy Level Other investments — — $ 91.8 $ 1,249.4 2 Total long-term debt, excluding leases and current maturities $ 423.4 $ 439.4 2 $ 423.1 $ 449.8 2 We own shares of ordinary voting stock of Sartorius AG (Sartorius), of Goettingen, Germany, a process technology supplier to the biotechnology, pharmaceutical, chemical and food and beverage industries. We own over 37% of the outstanding voting shares (excluding treasury shares) of Sartorius as of June 30, 2018 . The Sartorius family trust and Sartorius family members hold a controlling interest of the outstanding voting shares. We do not have any representative or designee on Sartorius’ Board of Directors, nor do we have the ability to exercise significant influence over the operating and financial policies of Sartorius. As of June 30, 2018 , due to the adoption of

3. Intangible Assets, Goodwill

3. Intangible Assets, Goodwill and Other	6 Months Ended
	Jun. 30, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets Disclosure	GOODWILL AND OTHER PURCHASED INTANGIBLE ASSETS Changes to goodwill by segment were as follows (in millions): Life Science Clinical Diagnostics Total Balances as of January 1, 2018: Goodwill $ 234.7 $ 324.6 $ 559.3 Accumulated impairment losses (35.9 ) (17.3 ) (53.2 ) Goodwill, net 198.8 307.3 506.1 Divestiture — (1.4 ) (1.4 ) Currency fluctuations (0.2 ) (4.5 ) (4.7 ) Balances as of June 30, 2018: Goodwill 234.5 318.7 553.2 Accumulated impairment losses (35.9 ) (17.3 ) (53.2 ) Goodwill, net $ 198.6 $ 301.4 $ 500.0 In March 2018, we wrote off $1.4 million of goodwill from our Clinical Diagnostics segment as a result of a divestiture of a product line. Other than goodwill, we have no intangible assets with indefinite lives. Information regarding our identifiable purchased intangible assets with definite lives is as follows (in millions): June 30, 2018 Average Remaining Life (years) Purchase Price Accumulated Amortization Net Carrying Amount Customer relationships/lists 1-7 $ 89.6 $ (65.7 ) $ 23.9 Know how 1-8 192.3 (158.6 ) 33.7 Developed product technology 3-11 131.8 (74.2 ) 57.6 Licenses 1-11 76.4 (38.5 ) 37.9 Tradenames 3-6 3.9 (3.2 ) 0.7 Covenants not to compete 1-8 7.9 (3.7 ) 4.2 Total definite-lived intangible assets $ 501.9 $ (343.9 ) $ 158.0 December 31, 2017 Average Remaining Life (years) Purchase Price Accumulated Amortization Net Carrying Amount Customer relationships/lists 1-7 $ 92.3 $ (64.4 ) $ 27.9 Know how 1-8 194.9 (157.9 ) 37.0 Developed product technology 1-12 133.3 (70.3 ) 63.0 Licenses 1-12 76.7 (36.0 ) 40.7 Tradenames 1-6 3.9 (3.0 ) 0.9 Covenants not to compete 1-8 7.9 (3.3 ) 4.6 Total definite-lived intangible assets $ 509.0 $ (334.9 ) $ 174.1 Amortization expense related to purchased intangible assets is as follows (in millions): Three Months Ended Six Months Ended June 30, June 30, 2018 2017 2018 2017 Amortization expense $ 7.4 $ 8.7 $ 14.8 $ 15.6

4. Supplemental Cash Flow Info

4. Supplemental Cash Flow Information (Notes)	6 Months Ended
	Jun. 30, 2018
Supplemental Cash Flow Elements [Abstract]
Cash Flow, Supplemental Disclosures [Text Block]	SUPPLEMENTAL CASH FLOW INFORMATION The reconciliation of net income to net cash provided by operating activities is as follows (in millions): Six Months Ended June 30, 2018 June 30, 2017 Net income $ 924.8 $ 17.4 Adjustments to reconcile net income to net cash provided by (used in) operating activities: Depreciation and amortization 68.7 70.7 Share-based compensation 12.1 10.6 Losses on dispositions of securities 0.6 0.3 Changes in fair market value of equity securities (1,102.3 ) — Gain on divestiture of a product line (5.1 ) — Losses on dispositions of fixed assets 0.8 — Gain on sale of land (4.1 ) — Changes in fair value of contingent consideration (2.4 ) (8.7 ) Decrease (increase) in accounts receivable 52.5 (1.8 ) Increase in inventories (11.7 ) (37.9 ) Increase in other current assets (5.9 ) (14.8 ) Decrease in accounts payable and other current liabilities (43.7 ) (24.2 ) Decrease in income taxes payable (20.9 ) (13.2 ) Increase (decrease) in deferred income taxes 246.2 (3.1 ) Net increase in other long-term assets/liabilities 8.6 11.0 Net cash provided by operating activities $ 118.2 $ 6.3

5. Long-Term Debt

5. Long-Term Debt	6 Months Ended
	Jun. 30, 2018
Debt Disclosure [Abstract]
Long-term Debt	LONG-TERM DEBT The principal components of long-term debt are as follows (in millions): June 30, December 31, 4.875% Senior Notes due 2020 principal amount $ 425.0 $ 425.0 Less unamortized discount and debt issuance costs (1.6 ) (1.9 ) 4.875% Senior Notes less unamortized discount and debt issuance costs 423.4 423.1 Capital leases and other debt 17.1 11.9 440.5 435.0 Less current maturities (1.7 ) (0.4 ) Long-term debt $ 438.8 $ 434.6 Senior Notes due 2020 In December 2010, Bio-Rad sold $425.0 million principal amount of Senior Notes due 2020 ( 4.875% Notes). The sale yielded net cash proceeds of $422.6 million at an effective rate of 4.946% . The 4.875% Notes pay a fixed rate of interest of 4.875% per year. We have the option to redeem any or all of the 4.875% Notes at any time at a redemption price of 100% of the principal amount (plus a specified make-whole premium as defined in the indenture governing the 4.875% Notes) and accrued and unpaid interest thereon to the redemption date. Our obligations under the 4.875% Notes are not secured and rank equal in right of payment with all of our existing and future unsubordinated indebtedness. Certain covenants apply at each year end to the 4.875% Notes including limitations on the following: liens, sale and leaseback transactions, mergers, consolidations or sales of assets and other covenants. There are no restrictive covenants relating to total indebtedness, interest coverage, stock repurchases, recapitalizations, dividends and distributions to shareholders or current ratios. Credit Agreement In June 2014, Bio-Rad entered into a $200.0 million unsecured Credit Agreement. Borrowings under the Credit Agreement are on a revolving basis and can be used to make permitted acquisitions, for working capital and for other general corporate purposes. We had no outstanding borrowings under the Credit Agreement as of June 30, 2018 or December 31, 2017 , however $0.5 million was utilized for domestic standby letters of credit that reduced our borrowing availability as of June 30, 2018 . The Credit Agreement matures in June 2019 . If we had borrowed against our Credit Agreement, the borrowing rate would have been 3.46% at June 30, 2018 . The Credit Agreement requires Bio-Rad to comply with certain financial ratios and covenants, among other things. These ratios and covenants include a leverage ratio test and an interest coverage test, as well as restrictions on our ability to declare or pay dividends, incur debt, guarantee debt, enter into transactions with affiliates, merge or consolidate, sell assets, make investments and create liens. We were in compliance with all of these ratios and covenants as of June 30, 2018

6. Accumulated Other Comprehen

6. Accumulated Other Comprehensive Income 6. Accumulated Other Comprehensive Income (Notes)	6 Months Ended
	Jun. 30, 2018
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	. ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) Accumulated other comprehensive income included in our Condensed Consolidated Balance Sheets consists of the following components (in millions): Foreign currency translation adjustments Foreign other post-employment benefits adjustments Net unrealized holding gains on available-for-sale investments Total accumulated other comprehensive income Balances as of January 1, 2018*: $ 77.4 $ (22.3 ) $ 4.5 $ 59.6 Other comprehensive (loss) income, before reclassifications (77.6 ) 0.5 (2.1 ) (79.2 ) Amounts reclassified from Accumulated other comprehensive income — 0.8 0.2 1.0 Income tax effects — (0.1 ) — (0.1 ) Other comprehensive (loss) income, net of income taxes (77.6 ) 1.2 (1.9 ) (78.3 ) Balances as of June 30, 2018: $ (0.2 ) $ (21.1 ) $ 2.6 $ (18.7 ) Foreign currency translation adjustments Foreign other post-employment benefits adjustments Net unrealized holding gains on available-for-sale investments Total accumulated other comprehensive income Balances as of January 1, 2017: $ 1.3 $ (18.6 ) $ 435.0 $ 417.7 Other comprehensive income (loss), before reclassifications 60.5 (2.5 ) 213.2 271.2 Amounts reclassified from Accumulated other comprehensive income — — — — Income tax effects — 0.5 (78.5 ) (78.0 ) Other comprehensive income (loss), net of income taxes 60.5 (2.0 ) 134.7 193.2 Balances as of June 30, 2017: $ 61.8 $ (20.6 ) $ 569.7 $ 610.9 *The beginning balance has been updated as a result of adopting ASU 2016-01. See Note 1, "Basis of Presentation and Use of Estimates" under "Recent Accounting Standards Updates." The amounts reclassified out of Accumulated other comprehensive income into the Condensed Consolidated Statements of Income, with presentation location, were as follows: Income before taxes impact (in millions): Three Months Ended Six Months Ended June 30, June 30, Components of Comprehensive income 2018 2017 2018 2017 Location Amortization of foreign other post-employment benefit items $ (0.5 ) $ 0.2 $ (0.8 ) $ — Other (income) expense, net Net holding (losses) gains on equity securities and available-for-sale investments $ (0.1 ) $ (0.2 ) $ (0.2 ) $ — Other (income) expense, net

7. Earnings Per Share

7. Earnings Per Share	6 Months Ended
	Jun. 30, 2018
Earnings Per Share [Abstract]
Earnings Per Share	. EARNINGS PER SHARE Basic earnings per share is computed by dividing net income attributable to Bio-Rad by the weighted average number of common shares outstanding for that period. Diluted earnings per share takes into account the effect of dilutive instruments, such as stock options and restricted stock, and uses the average share price for the period in determining the number of potential common shares that are to be added to the weighted average number of shares outstanding. Potential common shares are excluded from the diluted earnings per share calculation if the effect of including such securities would be anti-dilutive. The weighted average number of common shares outstanding used to calculate basic and diluted earnings per share, and the anti-dilutive shares that are excluded from the diluted earnings per share calculation are as follows (in thousands): Three Months Ended Six Months Ended June 30, June 30, 2018 2017 2018 2017 Basic weighted average shares outstanding 29,814 29,613 29,801 29,597 Effect of potentially dilutive stock options and restricted stock awards 405 393 396 365 Diluted weighted average common shares 30,219 30,006 30,197 29,962 Anti-dilutive shares 13 — 13 15

8. Other Income and Expenses

8. Other Income and Expenses	6 Months Ended
	Jun. 30, 2018
Other Income and Expenses [Abstract]
Other Income and Other Expense Disclosure	. OTHER INCOME AND EXPENSE, NET Other (income) expense, net includes the following components (in millions): Three Months Ended Six Months Ended June 30, June 30, 2018 2017 2018 2017 Interest and investment income $ (16.2 ) $ (12.0 ) $ (18.3 ) $ (13.1 ) Net realized loss (gain) on investments 0.1 0.2 0.2 (0.1 ) Gain on sale of land — — (4.1 ) — Gain on divestiture of product line — — (5.1 ) — Other expense 0.2 0.4 0.3 0.8 Other (income) expense, net $ (15.9 ) $ (11.4 ) $ (27.0 ) $ (12.4 )

9. Income Taxes

9. Income Taxes	6 Months Ended
	Jun. 30, 2018
Income Tax Disclosure [Abstract]
Income Taxes	. INCOME TAXES Our effective income tax rate was 21% and (350)% for the three months ended June 30, 2018 and 2017 , respectively. Our effective income tax rate was 23% and 18% for the six months ended June 30, 2018 and 2017 , respectively. The effective tax rate for the three and six months ended June 30, 2018 was driven primarily by the large gain on equity investments taxable at the U.S. federal statutory rate of 21% . The effective tax rate for the three and six months ended June 30, 2017 was lower than the U.S. federal statutory rate of 35% due to the impact of second quarter discrete items on low pre-tax income. In accordance with SAB 118, our accounting for the following elements of the Tax Act was incomplete at December 31, 2017. However, we were able to make reasonable estimates of certain effects and, therefore, recorded provisional estimates as follows: • Our deferred tax assets and liabilities were measured at the enacted tax rate that will apply when these temporary differences are expected to be realized or settled. • The Tax Act imposes a Transition Tax payable over eight years. The Transition Tax is assessed on the U.S. shareholders’ share of certain foreign corporations’ accumulated untaxed foreign earnings. Earnings in the form of cash and cash equivalents are taxed at a rate of 15.5% and all other earnings are taxed at a rate of 8.0%. In December 2017, we recorded a provisional income tax expense of $55 million for Transition Tax. Our accounting for certain other elements of the Tax Act was incomplete, and we were not able to make reasonable estimates of those effects. For example, we did not make a determination as to our accounting policy with respect to the new Global Intangible Low-Taxed Income ("GILTI"). For the period ended June 30, 2018 , we did not record adjustments to our provisional amounts. We will continue our analysis of these provisional amounts during the measurement period and may adjust these estimates as further regulatory guidance becomes available. We assess our ability to realize our net deferred tax assets on a quarterly basis and establish a valuation allowance if it is more-likely-than-not that some portion of the deferred tax assets will not be realized in the foreseeable future. Due to the weight of negative evidence, including our history of losses in certain jurisdictions, we believe that it is more-likely-than-not that certain foreign deferred tax assets will not be realized as of June 30, 2018 . Accordingly, we have maintained a valuation allowance on such deferred tax assets. Our income tax returns are routinely audited by U.S. federal, state and foreign tax authorities. We are currently under examination by many of these tax authorities. There are differing interpretations of tax laws and regulations, and as a result, significant disputes may arise with these tax authorities involving issues of the timing and amount of deductions and allocations of income among various tax jurisdictions. We evaluate our exposures associated with our tax filing positions on a quarterly basis. We record liabilities for unrecognized tax benefits related to uncertain tax positions. We do not believe any currently pending uncertain tax positions will have a material adverse effect on our condensed consolidated financial statements, although an adverse resolution of one or more of these uncertain tax positions in any period may have a material impact on the results of operations for that period. As of June 30, 2018 , based on the expected outcome of certain examinations or as a result of the expiration of statute of limitations for certain jurisdictions, we believe that within the next 12 months it is reasonably possible that our previously unrecognized tax benefits could decrease by up to $3 million

10. Segment Information

10. Segment Information	6 Months Ended
	Jun. 30, 2018
Segment Reporting [Abstract]
Segment Information	EGMENT INFORMATION Information regarding industry segments for the three months ended June 30, 2018 and 2017 is as follows (in millions): Life Science Clinical Diagnostics Other Operations Segment net sales 2018 $ 217.8 $ 354.0 $ 4.1 2017 $ 179.4 $ 322.1 $ 3.2 Segment net profit (loss) 2018 $ 12.2 $ 27.8 $ — 2017 $ (22.9 ) $ 18.5 $ 0.2 Information regarding industry segments for the six months ended June 30, 2018 and 2017 is as follows (in millions): Life Science Clinical Diagnostics Other Operations Segment net sales 2018 $ 415.6 $ 704.8 $ 7.0 2017 $ 353.6 $ 644.4 $ 6.7 Segment net profit (loss) 2018 $ 15.5 $ 64.4 $ — 2017 $ (41.7 ) $ 60.1 $ 0.4 Prior year amounts have been adjusted (see Note 1 to the condensed consolidated financial statements in regard to ASU 2017-07 for pension and other postretirement benefits). Segment results are presented in the same manner as we present our operations internally to make operating decisions and assess performance. Net corporate operating, interest and other expense for segment results consists of receipts and expenditures that are not the primary responsibility of segment operating management and therefore are not allocated to the segments for performance assessment by our chief operating decision maker. Interest expense is charged to segments based on the carrying amount of inventory and receivables employed by that segment. For the three and six months ended June 30, 2018 compared to the same periods in 2017, our Life Science segment had increased sales and gross profit, along with lower Research and Development expense. In addition, the Life Science segment gross margin included a $10.0 million one-time expense associated with the RainDance acquisition in the first quarter of 2017. During the second quarter of 2017, our Clinical Diagnostics segment had an asset purchase for an early stage device for $7.5 million that was recorded in Research and development expense. The following reconciles total segment profit to consolidated income before taxes (in millions): Three Months Ended Six Months Ended June 30, June 30, 2018 2017 2018 2017 Total segment profit (loss) $ 40.0 $ (4.2 ) $ 79.9 $ 18.8 Foreign currency exchange losses, net — (2.5 ) (1.2 ) (4.3 ) Net corporate operating, interest and other expense not allocated to segments (2.2 ) (3.6 ) (4.2 ) (5.6 ) Change in fair market value of equity securities 286.4 — 1,102.3 — Other income (expense), net 15.9 11.4 27.0 12.4 Consolidated income before income taxes $ 340.1 $ 1.1 $ 1,203.8 $ 21.3

11. Legal Proceedings

11. Legal Proceedings	6 Months Ended
	Jun. 30, 2018
Loss Contingency, Information about Litigation Matters [Abstract]
Legal Proceedings.	11. LEGAL PROCEEDINGS On May 27, 2015, our former general counsel, Sanford S. Wadler, filed a lawsuit in the U.S. District Court, Northern District of California, against us and four of our then current directors and one former director. The plaintiff’s suit alleged whistleblower retaliation in violation of the Sarbanes-Oxley Act and the Dodd-Frank Act for raising FCPA-related concerns. Mr. Wadler also alleged wrongful termination in violation of public policy, non-payment of wages and waiting time penalties in violation of the California Labor Code. The plaintiff sought back pay, compensatory damages for lost wages, earnings, retirement benefits and other employee benefits, compensation for mental pain and anguish and emotional distress, waiting time penalties, punitive damages, litigation costs (including attorneys’ fees) and reinstatement of employment. On July 28, 2015 we filed a motion to dismiss the plaintiff's complaint and specifically requested dismissal of the claims alleged against us under the Dodd-Frank Act and California Labor Code 1102.5 and the claims against the directors under the Sarbanes-Oxley Act and the Dodd-Frank Act. On October 23, 2015, the District Court granted our motion with respect to the alleged violations of the Sarbanes-Oxley Act against all the director defendants except Norman Schwartz with prejudice. The Court denied our motion to dismiss the claims under the Dodd-Frank Act as against both us and the director defendants. The trial commenced on January 17, 2017 and concluded on February 6, 2017. Mr. Wadler was awarded $10.92 million , plus prejudgment interest of $141,608 , post-judgment interest, and Mr. Wadler’s litigation costs, expert witness fees, and reasonable attorneys’ fees as approved by the Court. We have provided for the judgment, interest and Mr. Wadler's litigation costs. On June 6, 2017 we filed a notice of appeal with the United States Court of Appeals for the Ninth Circuit.

12. Restructuring Costs (Notes)

12. Restructuring Costs (Notes)	6 Months Ended
	Jun. 30, 2018
Restructuring Costs [Abstract]
Restructuring and Related Activities Disclosure [Text Block]	12. RESTRUCTURING COSTS Restructuring Costs for European Reorganization In May, 2016, we announced that we would take certain actions in our Europe geographic region designed to better align expenses to our revenue and gross margin profile and position us for improved operating performance. These actions, aligned with the evolution of our organization structure and coordinated with the implementation of our global single instance ERP platform, are expected to be incurred through 2019. From inception of May 2016 to June 30, 2018, total expenses were $12.9 million . We recorded $(0.1) million of adjustments in restructuring charges related to severance and other employee benefits for the three and six months ended June 30, 2018 . The liability of $4.2 million as of June 30, 2018 consisted of $4.1 million recorded in Accrued payroll and employee benefits and $0.1 million recorded in Other long-term liabilities in the Condensed Consolidated Balance Sheets. The amounts recorded were reflected in Cost of goods sold of $(0.1) million and in Selling, general and administrative expense of less than $(0.1) million in the Condensed Consolidated Statements of Income for the three and six months ended June 30, 2018 . The following table summarizes the activity of our European reorganization restructuring reserves for severance (in millions): Life Science Clinical Diagnostics Total Balance as of January 1, 2018 $ 2.2 $ 4.1 $ 6.3 Charged to expense — — — Adjustment to expense — (0.1 ) (0.1 ) Cash payments (0.6 ) (1.3 ) (1.9 ) Foreign currency translation gains — (0.1 ) (0.1 ) Balance as of June 30, 2018 $ 1.6 $ 2.6 $ 4.2 Restructuring Costs for Termination of a Diagnostics Research and Development Project and a Facility Closure In December 2017, we announced the termination of a diagnostics research and development project in Europe. From inception of December 2017 to June 30, 2018, total expenses were $20.4 million . We recorded $(0.6) million and $(0.7) million of adjustments in restructuring charges related to severance and employee benefits, and exit costs for the three and six months ended June 30, 2018 , respectively. The adjustments were due to a decrease in severance accrual as a result of a reduction in the number of employees being terminated than originally estimated, net of an increase in exit costs accrual as a result of proposed legal settlement. In June 2018, we announced the closure of a manufacturing facility in Germany. As a result, we recorded $1.3 million of expense in restructuring charges related to severance and employee benefits for the three and six months ended June 30, 2018 . Restructuring charges for the termination of a diagnostics research and development project and the facility closure are both included in our Clinical Diagnostics segment's results of operations. The respective amounts recorded for the quarter and year to date ended June 30, 2018 were reflected in Cost of goods sold of $1.3 million and $1.3 million , in Selling, general and administrative expense of $(0.3) million and $(0.1) million , and in Research and development expense of $(0.3) million and $(0.6) million in the Condensed Consolidated Statements of Income. The liability of $11.7 million as of June 30, 2018 consisted of $7.2 million recorded in Accrued payroll and employee benefits, $3.2 million recorded in Other current liabilities, and $1.3 million recorded in Other long term liabilities in the Condensed Consolidated Balance Sheets. The following table summarizes the activity for the termination of the diagnostics research and development project and the facility closure restructuring reserves for severance and exit costs (in millions): 2018 Balance as of January 1 $ 14.1 Charged to expense 1.3 Adjustment to expense (0.7 ) Cash payments (2.7 ) Foreign currency translation gains (0.3 ) Balance as of June 30 $ 11.7

1. Basis of Presentation and U

1. Basis of Presentation and Use of Estimates Organization, Consolidation and Presentation of Financial Statements (Policies)	6 Months Ended
	Jun. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
New Accounting Pronouncements, Policy [Policy Text Block]	Revenue Recognition On January 1, 2018, the Company adopted Accounting Standards Codification ("ASC") 606, "Revenue from Contracts with Customers," using the modified retrospective method applied to those contracts which were not completed as of January 1, 2018. Results for reporting periods beginning after January 1, 2018 are presented under ASC 606, while prior period amounts are not adjusted and continue to be reported under prior revenue guidance ASC 605, "Revenue Recognition." We recorded a net reduction to opening retained earnings of $0.1 million as of January 1, 2018 due to the cumulative impact of adopting ASC 606 with the impact primarily related to a customer loyalty program in the United States for which the resulting non-cash consideration is treated as variable consideration under the new revenue recognition accounting standard. The impact to revenue as a result of applying ASC 606 as compared to ASC 605 for the six months ended June 30, 2018 was not significant. The Company recognizes revenue from operations through the sale of products, services, and rental of instruments. Revenue from contracts with customers is recognized upon transfer of control of promised products or services to customers in an amount that reflects the consideration we expect to receive in exchange for those products or services. We enter into contracts that can include various combinations of products and services, which are generally accounted for as distinct performance obligations. Revenue is recognized net of any taxes collected from customers (sales tax, value added tax, etc.), which are subsequently remitted to government authorities. Our contracts from customers often include promises to transfer multiple products and services to a customer. Determining whether products and services are considered distinct performance obligations that should be accounted for separately versus together may require significant judgment and may or may not impact the timing of revenue recognition. Revenue associated with equipment that requires factory installation is not recorded until installation is complete and customer acceptance, if required, has occurred. Certain equipment requires installation due to the fact that the instruments are being operated in a clinical/laboratory environment, and the installation services could result in modification of the equipment in order to ensure that the instruments are working according to specifications of the customer which are subject to validation tests upon completion of the installation. Accordingly, in these cases, the delivery of the equipment and the installation are separate performance obligations. The Company will recognize the transaction price allocated to the equipment only upon customer acceptance, as the transfer of control has occurred in relation to the equipment at that point in time as the customer has the ability to direct the use of and obtain substantially all of the remaining benefits from the asset. The transaction price allocated to the installation services is also recognized upon completion of the services because without the completion of the installation services and related customer acceptance the customer cannot receive any of the benefits of the service. At the time revenue is recognized, a provision is recognized for estimated product returns as this right is considered variable consideration. Accordingly, when product revenues are recognized, the transaction price is reduced to the estimated amount that we expect to receive in exchange for transferring control for those products. Service revenues on extended warranty contracts are recognized ratably over the life of the service agreement as a stand-ready performance obligation. In those instances where the timing of revenue recognition differs from the timing of invoicing, we have determined that our contracts generally do not include a significant financing component. The primary purpose of our invoicing terms is to provide customers with simple and predictable methods of purchasing our products and services, not to either provide or receive financing to or from our customers. We record contract liabilities when cash payments are received or due in advance of our performance. We do not disclose the value of unsatisfied performance obligations for contracts with an original expected length of one year or less and for contracts in which we recognize revenue at the amount to which we have the right to invoice for services performed. Our payment terms vary by the type and location of our customer, and the products and services offered. The term between invoicing and when payment is due is not significant. Reagent Rental Agreements Reagent rental agreements are a diagnostic industry sales method that provides use of an instrument and consumables (reagents) to a customer on a per test basis. These agreements may also include maintenance of the underlying instruments retained at customer locations as well as initial training. The Company has concluded that the use of the instrument and related maintenance services (collectively known as “lease elements”) are not within the guidance of ASC 606 but rather ASC 840 Leases. Accordingly, the Company first allocates the transaction price between the lease elements and the non-lease elements based on relative standalone selling prices. The determination of the transaction price requires judgment and requires consideration of any fixed/minimum payments as well as estimates of variable consideration. After determining what portion of the transaction price should be allocated to the lease elements, any fixed consideration would be considered the minimum lease payment to be amortized straight line over the lease term and any variable consideration would be contingent rent to be recognized monthly as earned. For the portion of the transaction price allocated to the non-lease elements, which are principally the reagents, the related revenue will be recognized at a point in time when control transfers. Generally, the terms of the arrangements result in the transfer of control upon either (i) when the consumables are delivered or (ii) when the consumables are consumed by the customer. Revenue allocated to the lease elements are approximately 5% of total revenue and are included as part of the Net sales in our Condensed Consolidated Statements of Income. Contract costs: We apply a practical expedient to expense costs as incurred for costs to obtain a contract when the amortization period would have been one year or less. These costs, recorded within Selling, general and administrative expense, include our internal sales force compensation programs and certain partner sales incentive programs, as we have determined that annual compensation is commensurate with annual selling activities. Disaggregation of Revenue: The following table presents our revenues disaggregated by geographic region based primarily on the location of the use of the product or service (in millions, unaudited): Three Months Ended Six Months Ended June 30, June 30, 2018 2017 2018 2017 Europe $ 197.2 $ 163.9 $ 396.8 $ 348.9 Pacific Rim 122.0 107.5 231.4 202.3 United States 221.6 202.5 431.5 389.8 Other (primarily Canada and Latin America) 35.1 30.8 67.7 63.7 Total Net sales $ 575.9 $ 504.7 $ 1,127.4 $ 1,004.7 The disaggregation of our revenue by industry segment sources is presented in our Segment Information footnote (see Note 10). Deferred revenues represent mostly unrecognized fees billed or collected for extended service arrangements. Deferred revenues are recognized as (or when) the Company performs under the contract which is generally over time during the term of the service contract. A majority of our deferred revenue balance is classified as current with an expected length of one year or less. The increase in our total deferred revenue balance from $36.7 million at December 31, 2017 to $41.4 million at June 30, 2018 is primarily driven by cash payments received or due in advance of satisfying our performance obligations, offset by $22.4 million of revenue recognized that were included in our deferred revenue balance as of December 31, 2017 . We warrant certain equipment against defects in design, materials and workmanship, generally for a period of one year. Upon revenue recognition of that equipment, we establish, as part of Cost of goods sold, a provision for the expected costs of such warranty based on historical experience, specific warranty terms and customer feedback. A review is performed on a quarterly basis to assess the adequacy of our warranty accrual. Components of the warranty accrual, included in Other current liabilities and Other long-term liabilities in the Condensed Consolidated Balance Sheets, were as follows (in millions): January 1, 2018 $ 18.7 Provision for warranty 14.9 Actual warranty costs (17.5 ) June 30, 2018 $ 16.1 Recent Accounting Pronouncements Adopted In February 2018, the FASB issued Accounting Standards Update No. ("ASU") 2018-03, "Technical Corrections and Improvements to Financial Instruments - Recognition and Measurement of Financial Assets and Financial Liabilities." ASU 2018-03 amends certain items in ASU 2016-01 (see below) such as equity securities without a readily determinable fair value. ASU 2018-03 clarifies that an entity that uses the measurement alternative for equity securities without readily determinable fair values can change its measurement approach to fair value and once made the election is irrevocable. If an entity measures equity securities without readily determinable fair values at fair value, it must record a cumulative-effect adjustment to Retained earnings as of the beginning of the fiscal year in which the guidance is adopted. We adopted ASU 2018-03 on January 1, 2018 and made an irrevocable election to account for our investment of the ordinary shares of Sartorius AG at fair value (see ASU 2016-01 below). In January 2016, the FASB issued ASU 2016-01, "Recognition and Measurement of Financial Assets and Financial Liabilities." Amendments under ASU 2016-01, among other items, require that all equity investments in unconsolidated entities (other than those accounted for using the equity method of accounting) will generally be measured at fair value through earnings. Changes in fair value for equity securities will no longer be reported in other comprehensive income. For equity investments without readily determinable fair values, the cost method is also eliminated. We adopted ASU 2016-01 on January 1, 2018 and record equity investments without readily determinable fair values at cost, less impairment, and plus or minus subsequent adjustments for observable price changes and were valued at $0.6 million as of June 30, 2018 . Changes in the basis of these equity investments are reported in current earnings. For equity securities that are affected by ASU 2016-01 and ASU 2018-03, see Note 2 to the condensed consolidated financial statements, which primarily consists of our investment in Sartorius AG. The impact of the adoption of ASU 2016-01 and ASU 2018-03 on January 1, 2018 was through a cumulative-effect adjustment of $864.5 million to Total stockholders' equity by increasing Retained earnings of $1,543.7 million and decreasing Accumulated other comprehensive income of $679.2 million , including increasing Deferred income taxes by $232.9 million and an increase in Other investments of $1,097.4 million in our Condensed Consolidated Balance Sheet. As a result of ASU 2016-01 and ASU 2018-03 for the three and six months ended June 30, 2018 , we recorded $286.4 million and $1,102.3 million , respectively, for the Change in fair market value of equity securities in the Condensed Consolidated Statement of Income that resulted in a deferred tax expense for the three and six months ended June 30, 2018 of $62.6 million and $243.8 million , respectively. In March 2017, the FASB issued ASU 2017-07, "Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost," which changed how we present the net periodic benefit cost of our defined benefit pension and/or other postretirement plans. We adopted ASU 2017-07 on January 1, 2018 and applied the practical expedient to estimate amounts for comparative purposes utilizing the information disclosed in Note 12 to the consolidated financial statements in our Form 10-K for the year ended December 31, 2017. The interest costs are recorded in Interest expense, and the other costs are recorded in Other (income) expense, net in the Condensed Consolidated Statements of Income. For the second quarter of 2017 for interest costs and other costs, we reclassified $0.076 million , $0.538 million , and $0.036 million from Costs of goods sold (COGS), Selling, general and administrative expense (SG&A) and Research and development expense (R&D), respectively, to Interest expense of $0.275 million and Other (income) expense, net of $0.375 million . For the first six months of 2017 for interest costs and other costs, we reclassified $0.152 million , $1.076 million , and $0.072 million from COGS, SG&A and R&D, respectively, to Interest expense of $0.550 million and Other (income) expense, net of $0.750 million . In November 2016, the FASB issued ASU 2016-18, "Restricted Cash," which required us to cease to present transfers between cash and cash equivalents and restricted cash and restricted cash equivalents in the statement of cash flows. We adopted ASU 2016-18 on January 1, 2018 and updated the Condensed Consolidated Statements of Cash Flows to incorporate restricted cash included in Other current assets and Other assets of $1.1 million as of June 30, 2018 and $1.0 million as of June 30, 2017 . In October 2016, the FASB issued ASU 2016-16, "Intra-Entity Transfers of Assets Other Than Inventory," which required immediate recognition of income tax consequences of intercompany asset transfers, other than inventory transfers. We adopted ASU 2016-16 on January 1, 2018 on a modified retrospective basis through a cumulative-effect adjustment by decreasing Retained earnings by $17.6 million , and decreasing Prepaid taxes by $22.8 million and increasing Deferred tax assets by $5.2 million that are both recorded in Other assets in our Condensed Consolidated Balance Sheet. In August 2016, FASB issued ASU 2016-15, "Classification of Certain Cash Receipts and Cash Payments" and adopted it on January 1, 2018, which did not have an impact to our statement of cash flows presentation. In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers ("ASC 606"), an updated standard on revenue recognition. The new standard provides enhancements to the quality and consistency of how revenue is reported under the principle that revenue should be recognized in an amount that reflects the consideration to which the Company expects to be entitled in exchange for the transfer of promised goods or services. We adopted ASC 606 as of January 1, 2018 using the cumulative effect transition method as more fully described above under the caption “Revenue Recognition.” Recent Accounting Pronouncements to be Adopted In June 2016, the FASB issued ASU 2016-13, "Measurement of Credit Losses on Financial Instruments." ASU 2016-13 will replace the current incurred loss approach with an expected loss model for instruments measured at amortized cost and require entities to record allowances for available-for-sale debt securities rather than reduce the carrying amount under the current other-than-temporary impairment model. ASU 2016-13 is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. Early adoption is permitted for all entities for annual periods beginning after December 15, 2018, and interim periods therein. We are currently evaluating the effect ASU 2016-13 will have on our consolidated financial statements.
Revenue from Contract with Customer [Policy Text Block]	Revenue Recognition On January 1, 2018, the Company adopted Accounting Standards Codification ("ASC") 606, "Revenue from Contracts with Customers," using the modified retrospective method applied to those contracts which were not completed as of January 1, 2018. Results for reporting periods beginning after January 1, 2018 are presented under ASC 606, while prior period amounts are not adjusted and continue to be reported under prior revenue guidance ASC 605, "Revenue Recognition." We recorded a net reduction to opening retained earnings of $0.1 million as of January 1, 2018 due to the cumulative impact of adopting ASC 606 with the impact primarily related to a customer loyalty program in the United States for which the resulting non-cash consideration is treated as variable consideration under the new revenue recognition accounting standard. The impact to revenue as a result of applying ASC 606 as compared to ASC 605 for the six months ended June 30, 2018 was not significant. The Company recognizes revenue from operations through the sale of products, services, and rental of instruments. Revenue from contracts with customers is recognized upon transfer of control of promised products or services to customers in an amount that reflects the consideration we expect to receive in exchange for those products or services. We enter into contracts that can include various combinations of products and services, which are generally accounted for as distinct performance obligations. Revenue is recognized net of any taxes collected from customers (sales tax, value added tax, etc.), which are subsequently remitted to government authorities. Our contracts from customers often include promises to transfer multiple products and services to a customer. Determining whether products and services are considered distinct performance obligations that should be accounted for separately versus together may require significant judgment and may or may not impact the timing of revenue recognition. Revenue associated with equipment that requires factory installation is not recorded until installation is complete and customer acceptance, if required, has occurred. Certain equipment requires installation due to the fact that the instruments are being operated in a clinical/laboratory environment, and the installation services could result in modification of the equipment in order to ensure that the instruments are working according to specifications of the customer which are subject to validation tests upon completion of the installation. Accordingly, in these cases, the delivery of the equipment and the installation are separate performance obligations. The Company will recognize the transaction price allocated to the equipment only upon customer acceptance, as the transfer of control has occurred in relation to the equipment at that point in time as the customer has the ability to direct the use of and obtain substantially all of the remaining benefits from the asset. The transaction price allocated to the installation services is also recognized upon completion of the services because without the completion of the installation services and related customer acceptance the customer cannot receive any of the benefits of the service. At the time revenue is recognized, a provision is recognized for estimated product returns as this right is considered variable consideration. Accordingly, when product revenues are recognized, the transaction price is reduced to the estimated amount that we expect to receive in exchange for transferring control for those products. Service revenues on extended warranty contracts are recognized ratably over the life of the service agreement as a stand-ready performance obligation. In those instances where the timing of revenue recognition differs from the timing of invoicing, we have determined that our contracts generally do not include a significant financing component. The primary purpose of our invoicing terms is to provide customers with simple and predictable methods of purchasing our products and services, not to either provide or receive financing to or from our customers. We record contract liabilities when cash payments are received or due in advance of our performance. We do not disclose the value of unsatisfied performance obligations for contracts with an original expected length of one year or less and for contracts in which we recognize revenue at the amount to which we have the right to invoice for services performed. Our payment terms vary by the type and location of our customer, and the products and services offered. The term between invoicing and when payment is due is not significant. Reagent Rental Agreements Reagent rental agreements are a diagnostic industry sales method that provides use of an instrument and consumables (reagents) to a customer on a per test basis. These agreements may also include maintenance of the underlying instruments retained at customer locations as well as initial training. The Company has concluded that the use of the instrument and related maintenance services (collectively known as “lease elements”) are not within the guidance of ASC 606 but rather ASC 840 Leases. Accordingly, the Company first allocates the transaction price between the lease elements and the non-lease elements based on relative standalone selling prices. The determination of the transaction price requires judgment and requires consideration of any fixed/minimum payments as well as estimates of variable consideration. After determining what portion of the transaction price should be allocated to the lease elements, any fixed consideration would be considered the minimum lease payment to be amortized straight line over the lease term and any variable consideration would be contingent rent to be recognized monthly as earned. For the portion of the transaction price allocated to the non-lease elements, which are principally the reagents, the related revenue will be recognized at a point in time when control transfers. Generally, the terms of the arrangements result in the transfer of control upon either (i) when the consumables are delivered or (ii) when the consumables are consumed by the customer. Revenue allocated to the lease elements are approximately 5% of total revenue and are included as part of the Net sales in our Condensed Consolidated Statements of Income. Contract costs: We apply a practical expedient to expense costs as incurred for costs to obtain a contract when the amortization period would have been one year or less. These costs, recorded within Selling, general and administrative expense, include our internal sales force compensation programs and certain partner sales incentive programs, as we have determined that annual compensation is commensurate with annual selling activities. Disaggregation of Revenue: The following table presents our revenues disaggregated by geographic region based primarily on the location of the use of the product or service (in millions, unaudited): Three Months Ended Six Months Ended June 30, June 30, 2018 2017 2018 2017 Europe $ 197.2 $ 163.9 $ 396.8 $ 348.9 Pacific Rim 122.0 107.5 231.4 202.3 United States 221.6 202.5 431.5 389.8 Other (primarily Canada and Latin America) 35.1 30.8 67.7 63.7 Total Net sales $ 575.9 $ 504.7 $ 1,127.4 $ 1,004.7 The disaggregation of our revenue by industry segment sources is presented in our Segment Information footnote (see Note 10). Deferred revenues represent mostly unrecognized fees billed or collected for extended service arrangements. Deferred revenues are recognized as (or when) the Company performs under the contract which is generally over time during the term of the service contract. A majority of our deferred revenue balance is classified as current with an expected length of one year or less. The increase in our total deferred revenue balance from $36.7 million at December 31, 2017 to $41.4 million at June 30, 2018 is primarily driven by cash payments received or due in advance of satisfying our performance obligations, offset by $22.4 million of revenue recognized that were included in our deferred revenue balance as of December 31, 2017 . We warrant certain equipment against defects in design, materials and workmanship, generally for a period of one year. Upon revenue recognition of that equipment, we establish, as part of Cost of goods sold, a provision for the expected costs of such warranty based on historical experience, specific warranty terms and customer feedback. A review is performed on a quarterly basis to assess the adequacy of our warranty accrual. Components of the warranty accrual, included in Other current liabilities and Other long-term liabilities in the Condensed Consolidated Balance Sheets, were as follows (in millions): January 1, 2018 $ 18.7 Provision for warranty 14.9 Actual warranty costs (17.5 ) June 30, 2018 $ 16.1

1. Basis of Presentation and20

1. Basis of Presentation and Use of Estimates Schedule of Revenue from External Customers Geographic (Tables)	6 Months Ended
	Jun. 30, 2018
Segment Reporting Information [Line Items]
Revenue from External Customers by Geographic Areas [Table Text Block]	The following table presents our revenues disaggregated by geographic region based primarily on the location of the use of the product or service (in millions, unaudited): Three Months Ended Six Months Ended June 30, June 30, 2018 2017 2018 2017 Europe $ 197.2 $ 163.9 $ 396.8 $ 348.9 Pacific Rim 122.0 107.5 231.4 202.3 United States 221.6 202.5 431.5 389.8 Other (primarily Canada and Latin America) 35.1 30.8 67.7 63.7 Total Net sales $ 575.9 $ 504.7 $ 1,127.4 $ 1,004.7
Schedule of Product Warranty Liability [Table Text Block]	Components of the warranty accrual, included in Other current liabilities and Other long-term liabilities in the Condensed Consolidated Balance Sheets, were as follows (in millions): January 1, 2018 $ 18.7 Provision for warranty 14.9 Actual warranty costs (17.5 ) June 30, 2018 $ 16.1

2. Fair Value Measurements (Ta

2. Fair Value Measurements (Tables)	6 Months Ended
	Jun. 30, 2018
Fair Value Disclosures [Abstract]
Debt Securities, Available-for-sale [Table Text Block]	Available-for-sale investments consist of the following (in millions): June 30, 2018 Amortized Cost Unrealized Gains Unrealized Losses Estimated Fair Value Short-term investments: Corporate debt securities $ 224.9 $ 0.1 $ (1.4 ) $ 223.6 Municipal obligations 15.7 — (0.1 ) 15.6 Asset-backed securities 63.1 — (0.4 ) 62.7 U.S. government sponsored agencies 67.2 — (1.2 ) 66.0 Foreign government obligations 2.6 — — 2.6 373.5 0.1 (3.1 ) 370.5 Long-term investments: Asset-backed securities 0.2 — — 0.2 0.2 — — 0.2 Total $ 373.7 $ 0.1 $ (3.1 ) $ 370.7 The following is a summary of the amortized cost and estimated fair value of our debt securities at June 30, 2018 by contractual maturity date (in millions): Amortized Cost Estimated Fair Value Mature in less than one year $ 156.7 $ 156.4 Mature in one to five years 170.9 169.3 Mature in more than five years 46.1 45.0 Total $ 373.7 $ 370.7
Schedule of financial assets and liabilities carried at fair value on a recurring basis	Financial assets and liabilities carried at fair value and measured on a recurring basis as of June 30, 2018 are classified in the hierarchy as follows (in millions): Level 1 Level 2 Level 3 Total Financial Assets Carried at Fair Value: Cash equivalents: Commercial paper $ — $ 68.4 $ — $ 68.4 Time deposits 25.7 10.0 — 35.7 Money market funds 30.2 — — 30.2 Foreign government obligations — 1.8 — 1.8 U.S. government sponsored agencies — 6.0 — 6.0 Total cash equivalents (a) 55.9 86.2 — 142.1 Restricted investment 5.6 — — 5.6 Equity securities (b) 3,196.6 — — 3,196.6 Available-for-sale investments: Corporate debt securities — 223.6 — 223.6 U.S. government sponsored agencies — 66.0 — 66.0 Foreign government obligations — 2.6 — 2.6 Municipal obligations — 15.6 — 15.6 Asset-backed securities — 62.9 — 62.9 Total available-for-sale investments (c) — 370.7 — 370.7 Forward foreign exchange contracts (d) — 0.6 — 0.6 Total financial assets carried at fair value $ 3,258.1 $ 457.5 $ — $ 3,715.6 Financial Liabilities Carried at Fair Value: Forward foreign exchange contracts (e) $ — $ 1.0 $ — $ 1.0 Contingent consideration (f) — — 13.0 13.0 Total financial liabilities carried at fair value $ — $ 1.0 $ 13.0 $ 14.0 As of first quarter 2018, our equity securities are no longer reported as Available-for-sale investments due to the implementation of ASU 2016-01. Changes in fair value of equity securities are now reported on the Condensed Consolidated Statements of Income rather than Other Comprehensive Income (see Note 1). Financial assets and liabilities carried at fair value and measured on a recurring basis as of December 31, 2017 are classified in the hierarchy as follows (in millions): Level 1 Level 2 Level 3 Total Financial Assets Carried at Fair Value: Cash equivalents: Commercial paper $ — $ 36.0 $ — $ 36.0 Time deposits 43.7 10.0 — 53.7 U.S. government sponsored agencies — 11.2 — 11.2 Money market funds 3.4 — — 3.4 Total cash equivalents (a) 47.1 57.2 — 104.3 Restricted investment 5.6 — — 5.6 Available-for-sale investments: Corporate debt securities — 185.7 — 185.7 U.S. government sponsored agencies — 67.6 — 67.6 Foreign government obligations — 3.4 — 3.4 Brokered certificates of deposit — 0.7 — 0.7 Municipal obligations — 15.0 — 15.0 Marketable equity securities 973.4 — — 973.4 Asset-backed securities — 55.6 — 55.6 Total available-for-sale investments (c) 973.4 328.0 — 1,301.4 Forward foreign exchange contracts (d) — 0.5 — 0.5 Total financial assets carried at fair value $ 1,026.1 $ 385.7 $ — $ 1,411.8 Financial Liabilities Carried at Fair Value: Forward foreign exchange contracts (e) $ — $ 1.6 $ — $ 1.6 Contingent consideration (f) — — 16.7 16.7 Total financial liabilities carried at fair value $ — $ 1.6 $ 16.7 $ 18.3 (a) Cash equivalents are included in Cash and cash equivalents in the Condensed Consolidated Balance Sheets. (b) Equity securities are included in the following accounts in the Condensed Consolidated Balance Sheets (in millions): June 30, 2018 Short-term investments $ 44.7 Other investments 3,151.9 Total $ 3,196.6 The unrealized gains on our equity securities still held as of June 30, 2018 are $1,102.3 million and are primarily due to our investment in Sartorius AG and is recorded in our Condensed Consolidated Statements of Income due to the adoption of ASU 2016-01 (see Note 1). (c) Available-for-sale investments are included in the following accounts in the Condensed Consolidated Balance Sheets (in millions): June 30, 2018 December 31, 2017 Short-term investments $ 370.5 $ 371.2 Other investments 0.2 930.2 Total $ 370.7 $ 1,301.4 In accordance with our adoption of ASU 2016-01 January 1, 2018, our investment in Sartorius AG preferred shares, which was reported within marketable equity securities as Available-for-sale as of December 31, 2017 , is now reported as an Equity security as of June 30, 2018 (see Note 1 and footnote (b) above). (d) Forward foreign exchange contracts in an asset position are included in Other current assets in the Condensed Consolidated Balance Sheets. (e) Forward foreign exchange contracts in a liability position are included in Other current liabilities in the Condensed Consolidated Balance Sheets. (f) Contingent consideration liability is included in the following accounts in the Condensed Consolidated Balance Sheets (in millions): June 30, 2018 December 31, 2017 Other current liabilities $ 2.6 $ 2.7 Other long-term liabilities 10.4 14.0 Total $ 13.0 $ 16.7
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	The following table provides a reconciliation of the Level 3 analytical flow cytometer platform contingent consideration liabilities measured at estimated fair value (in millions): January 1, 2018 $ 16.7 Analytical flow cytometer platform: Payment of sales milestone (1.3 ) Decrease in estimated fair value of contingent consideration included in Selling, general and administrative expense (2.4 ) June 30, 2018 $ 13.0
Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]	The following table provides quantitative information about Level 3 inputs for fair value measurement of our analytical flow cytometer platform contingent consideration liability as of June 30, 2018 . Significant increases or decreases in these inputs in isolation could result in a significantly lower or higher fair value measurement. Valuation Technique Unobservable Input Analytical flow cytometer platform Probability-weighted income approach Sales milestones: Discount rate 11.1 % Cost of debt 4.8 %
Schedule of available-for-sale investments	Available-for-sale investments consist of the following (in millions): December 31, 2017 Amortized Cost Unrealized Gains Unrealized Losses Estimated Fair Value Short-term investments: Corporate debt securities $ 185.9 $ 0.3 $ (0.5 ) $ 185.7 Brokered certificates of deposit 0.7 — — 0.7 Municipal obligations 15.1 — (0.1 ) 15.0 Asset-backed securities 55.6 — (0.2 ) 55.4 U.S. government sponsored agencies 68.3 — (0.7 ) 67.6 Foreign government obligations 3.4 — — 3.4 Marketable equity securities 34.4 9.0 — 43.4 363.4 9.3 (1.5 ) 371.2 Long-term investments: Marketable equity securities 54.5 875.5 — 930.0 Asset-backed securities 0.2 — — 0.2 54.7 875.5 — 930.2 Total $ 418.1 $ 884.8 $ (1.5 ) $ 1,301.4
Summary of fair value of gross unrealized losses for investments with unrealized losses	The following is a summary of investments with gross unrealized losses and the associated fair value (in millions): June 30, 2018 December 31, 2017 Fair value of investments in a loss position 12 months or more $ 36.9 $ 43.9 Fair value of investments in a loss position less than 12 months $ 199.4 $ 168.7 Gross unrealized losses for investments in a loss position 12 months or more $ 0.9 $ 0.7 Gross unrealized losses for investments in a loss position less than 12 months $ 2.2 $ 0.8
Discussion of current derivative risk management	The following is a summary of our forward foreign exchange contracts (in millions): June 30, 2018 Contracts maturing in July through September 2018 to sell foreign currency: Notional value $ 37.8 Unrealized loss $ 0.1 Contracts maturing in July through September 2018 to purchase foreign currency: Notional value $ 327.6 Unrealized loss $ 0.5
Estimated fair value of financial instruments	The estimated fair value of the financial instruments discussed above and the level of the fair value hierarchy within which the fair value measurement is categorized are as follows (in millions): June 30, 2018 December 31, 2017 Carrying Amount Estimated Fair Value Fair Value Hierarchy Level Carrying Amount Estimated Fair Value Fair Value Hierarchy Level Other investments — — $ 91.8 $ 1,249.4 2 Total long-term debt, excluding leases and current maturities $ 423.4 $ 439.4 2 $ 423.1 $ 449.8 2

3. Intangible Assets, Goodwi22

3. Intangible Assets, Goodwill and Other (Tables)	6 Months Ended
	Jun. 30, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Changes to goodwill by segment	Changes to goodwill by segment were as follows (in millions): Life Science Clinical Diagnostics Total Balances as of January 1, 2018: Goodwill $ 234.7 $ 324.6 $ 559.3 Accumulated impairment losses (35.9 ) (17.3 ) (53.2 ) Goodwill, net 198.8 307.3 506.1 Divestiture — (1.4 ) (1.4 ) Currency fluctuations (0.2 ) (4.5 ) (4.7 ) Balances as of June 30, 2018: Goodwill 234.5 318.7 553.2 Accumulated impairment losses (35.9 ) (17.3 ) (53.2 ) Goodwill, net $ 198.6 $ 301.4 $ 500.0 In March 2018, we wrote off $1.4 million of goodwill from our Clinical Diagnostics segment as a result of a divestiture of a product line.
Schedule of identifiable purchased intangible assets with definite lives	Information regarding our identifiable purchased intangible assets with definite lives is as follows (in millions): June 30, 2018 Average Remaining Life (years) Purchase Price Accumulated Amortization Net Carrying Amount Customer relationships/lists 1-7 $ 89.6 $ (65.7 ) $ 23.9 Know how 1-8 192.3 (158.6 ) 33.7 Developed product technology 3-11 131.8 (74.2 ) 57.6 Licenses 1-11 76.4 (38.5 ) 37.9 Tradenames 3-6 3.9 (3.2 ) 0.7 Covenants not to compete 1-8 7.9 (3.7 ) 4.2 Total definite-lived intangible assets $ 501.9 $ (343.9 ) $ 158.0 December 31, 2017 Average Remaining Life (years) Purchase Price Accumulated Amortization Net Carrying Amount Customer relationships/lists 1-7 $ 92.3 $ (64.4 ) $ 27.9 Know how 1-8 194.9 (157.9 ) 37.0 Developed product technology 1-12 133.3 (70.3 ) 63.0 Licenses 1-12 76.7 (36.0 ) 40.7 Tradenames 1-6 3.9 (3.0 ) 0.9 Covenants not to compete 1-8 7.9 (3.3 ) 4.6 Total definite-lived intangible assets $ 509.0 $ (334.9 ) $ 174.1
Finite-lived Intangible Assets Amortization Expense [Table Text Block]	Amortization expense related to purchased intangible assets is as follows (in millions): Three Months Ended Six Months Ended June 30, June 30, 2018 2017 2018 2017 Amortization expense $ 7.4 $ 8.7 $ 14.8 $ 15.6

4. Supplemental Cash Flow In23

4. Supplemental Cash Flow Information Cash Flow, Supplemental Disclosure (Tables)	6 Months Ended
	Jun. 30, 2018
Supplemental Cash Flow Elements [Abstract]
Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]	The reconciliation of net income to net cash provided by operating activities is as follows (in millions): Six Months Ended June 30, 2018 June 30, 2017 Net income $ 924.8 $ 17.4 Adjustments to reconcile net income to net cash provided by (used in) operating activities: Depreciation and amortization 68.7 70.7 Share-based compensation 12.1 10.6 Losses on dispositions of securities 0.6 0.3 Changes in fair market value of equity securities (1,102.3 ) — Gain on divestiture of a product line (5.1 ) — Losses on dispositions of fixed assets 0.8 — Gain on sale of land (4.1 ) — Changes in fair value of contingent consideration (2.4 ) (8.7 ) Decrease (increase) in accounts receivable 52.5 (1.8 ) Increase in inventories (11.7 ) (37.9 ) Increase in other current assets (5.9 ) (14.8 ) Decrease in accounts payable and other current liabilities (43.7 ) (24.2 ) Decrease in income taxes payable (20.9 ) (13.2 ) Increase (decrease) in deferred income taxes 246.2 (3.1 ) Net increase in other long-term assets/liabilities 8.6 11.0 Net cash provided by operating activities $ 118.2 $ 6.3

5. Long-Term Debt (Tables)

5. Long-Term Debt (Tables)	6 Months Ended
	Jun. 30, 2018
Debt Disclosure [Abstract]
Schedule of Long-term Debt Instruments [Table Text Block]	The principal components of long-term debt are as follows (in millions): June 30, December 31, 4.875% Senior Notes due 2020 principal amount $ 425.0 $ 425.0 Less unamortized discount and debt issuance costs (1.6 ) (1.9 ) 4.875% Senior Notes less unamortized discount and debt issuance costs 423.4 423.1 Capital leases and other debt 17.1 11.9 440.5 435.0 Less current maturities (1.7 ) (0.4 ) Long-term debt $ 438.8 $ 434.6

6. Accumulated Other Compreh25

6. Accumulated Other Comprehensive Income 6. Accumulated Other Comprehensive Income (Tables)	6 Months Ended
	Jun. 30, 2018
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]	Accumulated other comprehensive income included in our Condensed Consolidated Balance Sheets consists of the following components (in millions): Foreign currency translation adjustments Foreign other post-employment benefits adjustments Net unrealized holding gains on available-for-sale investments Total accumulated other comprehensive income Balances as of January 1, 2018*: $ 77.4 $ (22.3 ) $ 4.5 $ 59.6 Other comprehensive (loss) income, before reclassifications (77.6 ) 0.5 (2.1 ) (79.2 ) Amounts reclassified from Accumulated other comprehensive income — 0.8 0.2 1.0 Income tax effects — (0.1 ) — (0.1 ) Other comprehensive (loss) income, net of income taxes (77.6 ) 1.2 (1.9 ) (78.3 ) Balances as of June 30, 2018: $ (0.2 ) $ (21.1 ) $ 2.6 $ (18.7 ) Foreign currency translation adjustments Foreign other post-employment benefits adjustments Net unrealized holding gains on available-for-sale investments Total accumulated other comprehensive income Balances as of January 1, 2017: $ 1.3 $ (18.6 ) $ 435.0 $ 417.7 Other comprehensive income (loss), before reclassifications 60.5 (2.5 ) 213.2 271.2 Amounts reclassified from Accumulated other comprehensive income — — — — Income tax effects — 0.5 (78.5 ) (78.0 ) Other comprehensive income (loss), net of income taxes 60.5 (2.0 ) 134.7 193.2 Balances as of June 30, 2017: $ 61.8 $ (20.6 ) $ 569.7 $ 610.9
Reclassification Out of Accumulated Other Comprehensive Income [Table Text Block]	The amounts reclassified out of Accumulated other comprehensive income into the Condensed Consolidated Statements of Income, with presentation location, were as follows: Income before taxes impact (in millions): Three Months Ended Six Months Ended June 30, June 30, Components of Comprehensive income 2018 2017 2018 2017 Location Amortization of foreign other post-employment benefit items $ (0.5 ) $ 0.2 $ (0.8 ) $ — Other (income) expense, net Net holding (losses) gains on equity securities and available-for-sale investments $ (0.1 ) $ (0.2 ) $ (0.2 ) $ — Other (income) expense, net

7. Earnings Per Share (Tables)

7. Earnings Per Share (Tables)	6 Months Ended
	Jun. 30, 2018
Earnings Per Share [Abstract]
Schedule of weighted-average common shares outstanding used to calculate basic and diluted earnings per shares and the anti-dilutive shares	The weighted average number of common shares outstanding used to calculate basic and diluted earnings per share, and the anti-dilutive shares that are excluded from the diluted earnings per share calculation are as follows (in thousands): Three Months Ended Six Months Ended June 30, June 30, 2018 2017 2018 2017 Basic weighted average shares outstanding 29,814 29,613 29,801 29,597 Effect of potentially dilutive stock options and restricted stock awards 405 393 396 365 Diluted weighted average common shares 30,219 30,006 30,197 29,962 Anti-dilutive shares 13 — 13 15

8. Other Income and Expenses (

8. Other Income and Expenses (Tables)	6 Months Ended
	Jun. 30, 2018
Other Income and Expenses [Abstract]
Schedule of other income (expense), net	Other (income) expense, net includes the following components (in millions): Three Months Ended Six Months Ended June 30, June 30, 2018 2017 2018 2017 Interest and investment income $ (16.2 ) $ (12.0 ) $ (18.3 ) $ (13.1 ) Net realized loss (gain) on investments 0.1 0.2 0.2 (0.1 ) Gain on sale of land — — (4.1 ) — Gain on divestiture of product line — — (5.1 ) — Other expense 0.2 0.4 0.3 0.8 Other (income) expense, net $ (15.9 ) $ (11.4 ) $ (27.0 ) $ (12.4 )

10. Segment Information (Table

10. Segment Information (Tables)	6 Months Ended
	Jun. 30, 2018
Segment Reporting [Abstract]
Net sales	Information regarding industry segments for the three months ended June 30, 2018 and 2017 is as follows (in millions): Life Science Clinical Diagnostics Other Operations Segment net sales 2018 $ 217.8 $ 354.0 $ 4.1 2017 $ 179.4 $ 322.1 $ 3.2 Segment net profit (loss) 2018 $ 12.2 $ 27.8 $ — 2017 $ (22.9 ) $ 18.5 $ 0.2 Information regarding industry segments for the six months ended June 30, 2018 and 2017 is as follows (in millions): Life Science Clinical Diagnostics Other Operations Segment net sales 2018 $ 415.6 $ 704.8 $ 7.0 2017 $ 353.6 $ 644.4 $ 6.7 Segment net profit (loss) 2018 $ 15.5 $ 64.4 $ — 2017 $ (41.7 ) $ 60.1 $ 0.4
Reconciliation of segment profit to consolidated income before taxes	The following reconciles total segment profit to consolidated income before taxes (in millions): Three Months Ended Six Months Ended June 30, June 30, 2018 2017 2018 2017 Total segment profit (loss) $ 40.0 $ (4.2 ) $ 79.9 $ 18.8 Foreign currency exchange losses, net — (2.5 ) (1.2 ) (4.3 ) Net corporate operating, interest and other expense not allocated to segments (2.2 ) (3.6 ) (4.2 ) (5.6 ) Change in fair market value of equity securities 286.4 — 1,102.3 — Other income (expense), net 15.9 11.4 27.0 12.4 Consolidated income before income taxes $ 340.1 $ 1.1 $ 1,203.8 $ 21.3

12. Restructuring Costs (Tables

12. Restructuring Costs (Tables)	6 Months Ended
	Jun. 30, 2018
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Costs [Table Text Block]	The following table summarizes the activity for the termination of the diagnostics research and development project and the facility closure restructuring reserves for severance and exit costs (in millions): 2018 Balance as of January 1 $ 14.1 Charged to expense 1.3 Adjustment to expense (0.7 ) Cash payments (2.7 ) Foreign currency translation gains (0.3 ) Balance as of June 30 $ 11.7 Life Science Clinical Diagnostics Total Balance as of January 1, 2018 $ 2.2 $ 4.1 $ 6.3 Charged to expense — — — Adjustment to expense — (0.1 ) (0.1 ) Cash payments (0.6 ) (1.3 ) (1.9 ) Foreign currency translation gains — (0.1 ) (0.1 ) Balance as of June 30, 2018 $ 1.6 $ 2.6 $ 4.2

1. Basis of Presentation and30

1. Basis of Presentation and Use of Estimates Organization, Consolidation and Presentation of Financial Statements (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017	Jan. 01, 2018	Dec. 31, 2017
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Net sales	$ 575,911	$ 504,666	$ 1,127,430	$ 1,004,717
Cost of goods sold	274,244	231,291	523,560	461,279
Deferred Revenue	41,400		41,400			$ 36,700
Revenue, Net	22,400
Retained earnings	4,281,275		4,281,275			1,830,439
Accumulated other comprehensive income	(18,710)		(18,710)			738,794
Total stockholders' equity	4,638,946		$ 4,638,946			2,930,250
Revenue Allocation Percent To Lease Elements			5.00%
Additional paid-in-capital	376,595		$ 376,595			$ 361,231
Unrealized Gain on Securities	286,398	0	1,102,332	0
Selling, general and administrative expense	210,425	212,489	419,555	406,891
Research and Development Expense	47,450	62,587	96,877	112,039
Interest expense	5,977	6,045	11,759	11,361
Prepaid Taxes					$ (22,800)
Deferred Tax Assets, Net, Noncurrent					5,200
Accounting Standards Update 2014-09 [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Retained earnings					100
Accounting Standards Update 2016-01 [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Other Investments	600		600
Accumulated other comprehensive income					679,200
Adjustments for New Accounting Pronouncement [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Investments					1,097,400
Deferred Income Tax Expense (Benefit)	62,600		243,800
Cost of goods sold		(76)		(152)
Retained earnings					1,543,700
Deferred Income Tax Assets, Net					232,900
Total stockholders' equity					864,500
Unrealized Gain on Securities	286,400		1,102,300
Selling, general and administrative expense		(538)		(1,076)
Research and Development Expense		(36)		(72)
Interest expense		275		550
Other Nonoperating Income (Expense)		375		750
Restricted Cash	1,100	1,000	1,100	1,000
Accounting Standards Update 2016-16 [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Retained earnings					$ (17,600)
Europe [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Net sales	197,200	163,900	396,800	348,900
Asia Pacific [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Net sales	122,000	107,500	231,400	202,300
UNITED STATES
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Net sales	221,600	202,500	431,500	389,800
Americas [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Net sales	$ 35,100	$ 30,800	$ 67,700	$ 63,700

1. Basis of Presentation and31

1. Basis of Presentation and Use of Estimates Warranty Rollforward (Details) $ in Millions	6 Months Ended
	Jun. 30, 2018USD ($)
Accounting Policies [Abstract]
Warranty accrual, beginning of period	$ 18.7
Provision for warranty	14.9
Actual warranty costs	(17.5)
Warranty accrual, end of period	$ 16.1

2. Fair Value Measurements Fai

2. Fair Value Measurements Fair Value Level Table (Details) - USD ($) $ in Millions		6 Months Ended
		Jun. 30, 2018	Dec. 31, 2017
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Unrealized Gain on Securities		$ 1,102.3
Debt Securities, Available-for-sale		370.7
Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Restricted Investments, at Fair Value		5.6	$ 5.6
Available-for-sale Securities	[1]		1,301.4
Equity Securities	[1]	3,196.6
Debt Securities, Available-for-sale	[1]	370.7
Forward Foreign Exchange Contracts, Asset, Fair Value Disclosure	[2]	0.6	0.5
Assets, Fair Value Disclosure		3,715.6	1,411.8
Forward Foreign Exchange Contracts, Liability, Fair Value Disclosure	[3]	1	1.6
Business Combination, Contingent Consideration, Liability	[4]	13	16.7
Liabilities, Fair Value Disclosure		14	18.3
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Restricted Investments, at Fair Value		5.6	5.6
Available-for-sale Securities	[1]		973.4
Equity Securities	[1]	3,196.6
Debt Securities, Available-for-sale	[1]	0
Forward Foreign Exchange Contracts, Asset, Fair Value Disclosure	[2]	0	0
Assets, Fair Value Disclosure		3,258.1	1,026.1
Forward Foreign Exchange Contracts, Liability, Fair Value Disclosure	[3]	0	0
Business Combination, Contingent Consideration, Liability	[4]	0	0
Liabilities, Fair Value Disclosure		0	0
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Restricted Investments, at Fair Value		0	0
Available-for-sale Securities	[1]		328
Equity Securities	[1]	0
Debt Securities, Available-for-sale	[1]	370.7
Forward Foreign Exchange Contracts, Asset, Fair Value Disclosure	[2]	0.6	0.5
Assets, Fair Value Disclosure		457.5	385.7
Forward Foreign Exchange Contracts, Liability, Fair Value Disclosure	[3]	1	1.6
Business Combination, Contingent Consideration, Liability	[4]	0	0
Liabilities, Fair Value Disclosure		1	1.6
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Restricted Investments, at Fair Value		0	0
Available-for-sale Securities	[1]		0
Equity Securities	[1]	0
Debt Securities, Available-for-sale	[1]	0
Forward Foreign Exchange Contracts, Asset, Fair Value Disclosure	[2]	0	0
Assets, Fair Value Disclosure		0	0
Forward Foreign Exchange Contracts, Liability, Fair Value Disclosure	[3]	0	0
Business Combination, Contingent Consideration, Liability	[4]	13	16.7
Liabilities, Fair Value Disclosure		13	16.7
US Treasury Securities [Member] | Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[5]	6
US Treasury Securities [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[5]	0
US Treasury Securities [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[5]	6
US Treasury Securities [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[5]	0
US Government Sponsored Agencies [Member] | Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[5]		11.2
US Government Sponsored Agencies [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[5]		0
US Government Sponsored Agencies [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[5]		11.2
US Government Sponsored Agencies [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[5]		0
Commercial Paper [Member] | Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[5]	68.4	36
Commercial Paper [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[5]	0	0
Commercial Paper [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[5]	68.4	36
Commercial Paper [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[5]	0	0
Foreign Government Obligations [Member] | Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[5]	1.8
Foreign Government Obligations [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[5]	0
Foreign Government Obligations [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[5]	1.8
Foreign Government Obligations [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[5]	0
Time Deposits [Member] | Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[5]	35.7	53.7
Time Deposits [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[5]	25.7	43.7
Time Deposits [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[5]	10	10
Time Deposits [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[5]	0	0
Money Market Funds [Member] | Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[5]	30.2	3.4
Money Market Funds [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[5]	30.2	3.4
Money Market Funds [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[5]	0	0
Money Market Funds [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[5]	0	0
Cash Equivalents [Member] | Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[5]	142.1	104.3
Cash Equivalents [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[5]	55.9	47.1
Cash Equivalents [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[5]	86.2	57.2
Cash Equivalents [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[5]	0	0
Brokered certificates of deposit [Member] | Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities	[1]		0.7
Brokered certificates of deposit [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities	[1]		0
Brokered certificates of deposit [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities	[1]		0.7
Brokered certificates of deposit [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities	[1]		0
Marketable Equity Securities [Member] | Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities	[1]		973.4
Marketable Equity Securities [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities	[1]		973.4
Marketable Equity Securities [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities	[1]		0
Marketable Equity Securities [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities	[1]		0
Municipal Obligations (Member) | Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities	[1]		15
Debt Securities, Available-for-sale	[1]	15.6
Municipal Obligations (Member) | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities	[1]		0
Debt Securities, Available-for-sale	[1]	0
Municipal Obligations (Member) | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities	[1]		15
Debt Securities, Available-for-sale	[1]	15.6
Municipal Obligations (Member) | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities	[1]		0
Debt Securities, Available-for-sale	[1]	0
Foreign Government Obligations [Member] | Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities	[1]		3.4
Debt Securities, Available-for-sale	[1]	2.6
Foreign Government Obligations [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities	[1]		0
Debt Securities, Available-for-sale	[1]	0
Foreign Government Obligations [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities	[1]		3.4
Debt Securities, Available-for-sale	[1]	2.6
Foreign Government Obligations [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities	[1]		0
Debt Securities, Available-for-sale	[1]	0
Corporate Debt Securities [Member] | Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities	[1]		185.7
Debt Securities, Available-for-sale	[1]	223.6
Corporate Debt Securities [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities	[1]		0
Debt Securities, Available-for-sale	[1]	0
Corporate Debt Securities [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities	[1]		185.7
Debt Securities, Available-for-sale	[1]	223.6
Corporate Debt Securities [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities	[1]		0
Debt Securities, Available-for-sale	[1]	0
US Government Sponsored Agencies [Member] | Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities	[1]		67.6
Debt Securities, Available-for-sale	[1]	66
US Government Sponsored Agencies [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities	[1]		0
Debt Securities, Available-for-sale	[1]	0
US Government Sponsored Agencies [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities	[1]		67.6
Debt Securities, Available-for-sale	[1]	66
US Government Sponsored Agencies [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities	[1]		0
Debt Securities, Available-for-sale	[1]	0
Asset-backed Securities [Member] | Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities	[1]		55.6
Debt Securities, Available-for-sale	[1]	62.9
Asset-backed Securities [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities	[1]		0
Debt Securities, Available-for-sale	[1]	0
Asset-backed Securities [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities	[1]		55.6
Debt Securities, Available-for-sale	[1]	62.9
Asset-backed Securities [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities	[1]		0
Debt Securities, Available-for-sale	[1]	0
Other Current Liabilities [Member] | Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Contingent Consideration, Liability		2.6	2.7
Other Noncurrent Liabilities [Member] | Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Contingent Consideration, Liability		10.4	14
Short-term Investments [Member] | Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities			371.2
Equity Securities		44.7
Debt Securities, Available-for-sale		370.5
Short-term Investments [Member] | Brokered certificates of deposit [Member] | Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities			0.7
Short-term Investments [Member] | Marketable Equity Securities [Member] | Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities			43.4
Short-term Investments [Member] | Municipal Obligations (Member) | Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities			15
Debt Securities, Available-for-sale		15.6
Short-term Investments [Member] | Foreign Government Obligations [Member] | Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities			3.4
Debt Securities, Available-for-sale		2.6
Short-term Investments [Member] | Corporate Debt Securities [Member] | Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities			185.7
Debt Securities, Available-for-sale		223.6
Short-term Investments [Member] | US Government Sponsored Agencies [Member] | Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities			67.6
Debt Securities, Available-for-sale		66
Short-term Investments [Member] | Asset-backed Securities [Member] | Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities			55.4
Debt Securities, Available-for-sale		62.7
Other Investments [Member] | Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities			$ 930.2
Equity Securities		3,151.9
Debt Securities, Available-for-sale		0.2
Analytical Flow Cytometer Platform [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Contingent Consideration, Liability		13
Sales milestone minimum amount [Member] | Analytical Flow Cytometer Platform [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, Low		$ 0
[1]	Available-for-sale investments are included in the following accounts in the Condensed Consolidated Balance Sheets (in millions): June 30, 2018 December 31, 2017 Short-term investments $ 370.5 $ 371.2 Other investments 0.2 930.2 Total $ 370.7 $ 1,301.4
[2]	Forward foreign exchange contracts in an asset position are included in Other current assets in the Condensed Consolidated Balance Sheets.
[3]	Forward foreign exchange contracts in a liability position are included in Other current liabilities in the Condensed Consolidated Balance Sheets.
[4]	Contingent consideration liability is included in the following accounts in the Condensed Consolidated Balance Sheets (in millions): June 30, 2018 December 31, 2017 Other current liabilities $ 2.6 $ 2.7 Other long-term liabilities 10.4 14.0 Total $ 13.0 $ 16.7
[5]	Cash equivalents are included in Cash and cash equivalents in the Condensed Consolidated Balance Sheets.

2. Fair Value Measurements 2.

2. Fair Value Measurements 2. Contingent Consideration (Details) - USD ($) $ in Millions		3 Months Ended	6 Months Ended	19 Months Ended
		Jun. 30, 2018	Jun. 30, 2018	Jun. 30, 2018	Dec. 31, 2017
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value		$ 13	$ 13	$ 13	$ 16.7
Analytical Flow Cytometer Platform [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration milestone payments		(1.3)	(1.3)
Business Combination, Contingent Consideration, Liability		$ 13	13	13
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances			$ (2.4)	$ (8.5)
Sales milestone percentage of annual invoices [Member] | Analytical Flow Cytometer Platform [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Acquisition, Contingent Consideration, Potential Percentage Payout		39.00%	39.00%	39.00%
Market Price of Risk [Member] | Analytical Flow Cytometer Platform [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Discount Rate			11.10%
Projected Volatility of Growth Rate [Member] | Analytical Flow Cytometer Platform [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Discount Rate			4.80%
Sales milestone percentage of annual invoices low [Member] | Analytical Flow Cytometer Platform [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Acquisition, Contingent Consideration, Potential Percentage Payout		20.00%	20.00%	20.00%
Sales milestone minimum amount [Member] | Analytical Flow Cytometer Platform [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, Low		$ 0	$ 0	$ 0
Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Contingent Consideration, Liability	[1]	13	13	13	16.7
Other Noncurrent Liabilities [Member] | Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Contingent Consideration, Liability		10.4	10.4	10.4	14
Other Current Liabilities [Member] | Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Contingent Consideration, Liability		$ 2.6	$ 2.6	$ 2.6	$ 2.7
[1]	Contingent consideration liability is included in the following accounts in the Condensed Consolidated Balance Sheets (in millions): June 30, 2018 December 31, 2017 Other current liabilities $ 2.6 $ 2.7 Other long-term liabilities 10.4 14.0 Total $ 13.0 $ 16.7

2. Foreign Exchange Forward Co

2. Foreign Exchange Forward Contracts (Details) $ in Millions	6 Months Ended
	Jun. 30, 2018USD ($)
Forward foreign exchange contract to sell foreign currency [Member]
Derivatives, Fair Value [Line Items]
Notional value	$ 37.8
Gain (Loss) on Foreign Currency Derivative Instruments not Designated as Hedging Instruments	(0.1)
Forward foreign exchange contract to purchase foreign currency [Member]
Derivatives, Fair Value [Line Items]
Notional value	327.6
Gain (Loss) on Foreign Currency Derivative Instruments not Designated as Hedging Instruments	$ (0.5)

2. Available-for-Sale Investme

2. Available-for-Sale Investments (Details) - USD ($) $ in Millions		Jun. 30, 2018	Dec. 31, 2017
Debt Securities, Available-for-sale [Line Items]
Amortized Cost		$ 373.7
Estimated Fair Value		370.7
Fair Value, Measurements, Recurring [Member]
Debt Securities, Available-for-sale [Line Items]
Available-for-sale Securities	[1]		$ 1,301.4
Amortized Cost		373.7
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax		0.1
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax		(3.1)
Estimated Fair Value	[1]	370.7
Available-for-sale Securities, Amortized Cost Basis			418.1
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax			884.8
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax			1.5
Fair Value, Measurements, Recurring [Member] | Corporate Debt Securities [Member]
Debt Securities, Available-for-sale [Line Items]
Available-for-sale Securities	[1]		185.7
Estimated Fair Value	[1]	223.6
Fair Value, Measurements, Recurring [Member] | Brokered certificates of deposit [Member]
Debt Securities, Available-for-sale [Line Items]
Available-for-sale Securities	[1]		0.7
Fair Value, Measurements, Recurring [Member] | Municipal obligations [Member]
Debt Securities, Available-for-sale [Line Items]
Available-for-sale Securities	[1]		15
Estimated Fair Value	[1]	15.6
Fair Value, Measurements, Recurring [Member] | Asset-backed Securities [Member]
Debt Securities, Available-for-sale [Line Items]
Available-for-sale Securities	[1]		55.6
Estimated Fair Value	[1]	62.9
Fair Value, Measurements, Recurring [Member] | Marketable Equity Securities [Member]
Debt Securities, Available-for-sale [Line Items]
Available-for-sale Securities	[1]		973.4
Fair Value, Measurements, Recurring [Member] | US Government Sponsored Agencies [Member]
Debt Securities, Available-for-sale [Line Items]
Available-for-sale Securities	[1]		67.6
Estimated Fair Value	[1]	66
Fair Value, Measurements, Recurring [Member] | Foreign Government Obligations [Member]
Debt Securities, Available-for-sale [Line Items]
Available-for-sale Securities	[1]		3.4
Estimated Fair Value	[1]	2.6
Fair Value, Measurements, Recurring [Member] | Other Long-term Investments [Member] | Asset-backed Securities [Member]
Debt Securities, Available-for-sale [Line Items]
Available-for-sale Securities			0.2
Amortized Cost		0.2
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax		0
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax		0
Estimated Fair Value		0.2
Available-for-sale Securities, Amortized Cost Basis			0.2
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax			0
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax			0
Fair Value, Measurements, Recurring [Member] | Other Long-term Investments [Member] | Marketable Equity Securities [Member]
Debt Securities, Available-for-sale [Line Items]
Available-for-sale Securities			930
Available-for-sale Securities, Amortized Cost Basis			54.5
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax			875.5
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax			0
Fair Value, Measurements, Recurring [Member] | Other Long-term Investments [Member] | Available-for-sale Securities [Member]
Debt Securities, Available-for-sale [Line Items]
Available-for-sale Securities			930.2
Available-for-sale Securities, Amortized Cost Basis			54.7
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax			875.5
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax			0
Fair Value, Measurements, Recurring [Member] | Other Long-term Investments [Member] | Debt Securities [Member]
Debt Securities, Available-for-sale [Line Items]
Amortized Cost		0.2
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax		0
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax		0
Estimated Fair Value		0.2
Fair Value, Measurements, Recurring [Member] | Short-term Investments [Member]
Debt Securities, Available-for-sale [Line Items]
Available-for-sale Securities			371.2
Estimated Fair Value		370.5
Fair Value, Measurements, Recurring [Member] | Short-term Investments [Member] | Corporate Debt Securities [Member]
Debt Securities, Available-for-sale [Line Items]
Available-for-sale Securities			185.7
Amortized Cost		224.9
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax		0.1
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax		(1.4)
Estimated Fair Value		223.6
Available-for-sale Securities, Amortized Cost Basis			185.9
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax			0.3
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax			0.5
Fair Value, Measurements, Recurring [Member] | Short-term Investments [Member] | Brokered certificates of deposit [Member]
Debt Securities, Available-for-sale [Line Items]
Available-for-sale Securities			0.7
Available-for-sale Securities, Amortized Cost Basis			0.7
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax			0
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax			0
Fair Value, Measurements, Recurring [Member] | Short-term Investments [Member] | Municipal obligations [Member]
Debt Securities, Available-for-sale [Line Items]
Available-for-sale Securities			15
Amortized Cost		15.7
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax		0
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax		(0.1)
Estimated Fair Value		15.6
Available-for-sale Securities, Amortized Cost Basis			15.1
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax			0
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax			0.1
Fair Value, Measurements, Recurring [Member] | Short-term Investments [Member] | Asset-backed Securities [Member]
Debt Securities, Available-for-sale [Line Items]
Available-for-sale Securities			55.4
Amortized Cost		63.1
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax		0
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax		(0.4)
Estimated Fair Value		62.7
Available-for-sale Securities, Amortized Cost Basis			55.6
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax			0
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax			0.2
Fair Value, Measurements, Recurring [Member] | Short-term Investments [Member] | Marketable Equity Securities [Member]
Debt Securities, Available-for-sale [Line Items]
Available-for-sale Securities			43.4
Available-for-sale Securities, Amortized Cost Basis			34.4
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax			9
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax			0
Fair Value, Measurements, Recurring [Member] | Short-term Investments [Member] | Available-for-sale Securities [Member]
Debt Securities, Available-for-sale [Line Items]
Available-for-sale Securities			371.2
Available-for-sale Securities, Amortized Cost Basis			363.4
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax			9.3
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax			1.5
Fair Value, Measurements, Recurring [Member] | Short-term Investments [Member] | US Government Sponsored Agencies [Member]
Debt Securities, Available-for-sale [Line Items]
Available-for-sale Securities			67.6
Amortized Cost		67.2
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax		0
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax		(1.2)
Estimated Fair Value		66
Available-for-sale Securities, Amortized Cost Basis			68.3
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax			0
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax			0.7
Fair Value, Measurements, Recurring [Member] | Short-term Investments [Member] | Foreign Government Obligations [Member]
Debt Securities, Available-for-sale [Line Items]
Available-for-sale Securities			3.4
Amortized Cost		2.6
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax		0
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax		0
Estimated Fair Value		2.6
Available-for-sale Securities, Amortized Cost Basis			3.4
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax			0
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax			0
Fair Value, Measurements, Recurring [Member] | Short-term Investments [Member] | Debt Securities [Member]
Debt Securities, Available-for-sale [Line Items]
Amortized Cost		373.5
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax		0.1
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax		(3.1)
Estimated Fair Value		370.5
Fair Value, Measurements, Recurring [Member] | Other Investments [Member]
Debt Securities, Available-for-sale [Line Items]
Available-for-sale Securities			$ 930.2
Estimated Fair Value		$ 0.2
[1]	Available-for-sale investments are included in the following accounts in the Condensed Consolidated Balance Sheets (in millions): June 30, 2018 December 31, 2017 Short-term investments $ 370.5 $ 371.2 Other investments 0.2 930.2 Total $ 370.7 $ 1,301.4

2. Amortized Cost and Fair Val

2. Amortized Cost and Fair Value of Debt Securities (Details) $ in Millions	Jun. 30, 2018USD ($)
Fair Value Disclosures [Abstract]
Mature in less than one year	$ 156.7
Mature in one to five years	170.9
Mature in more than five years	46.1
Total Amortized Cost	373.7
Mature in less than one year	156.4
Mature in one to five years	169.3
Mature in more than five years	45
Estimated Fair Value	$ 370.7

2. Fair Value and Gross Unreal

2. Fair Value and Gross Unrealized Losses with Unrealized Losses (Details) - USD ($) $ in Millions	6 Months Ended
	Jun. 30, 2018	Dec. 31, 2017
Price Change Debt Security	5.00%
Tolerable variance Level 2 debt security pricing	1.00%
Fair Value of Investments with Gross Unrealized Losses in loss position 12 months or more	$ 36.9	$ 43.9
Cost Method Investment, Percentage Owned	37.00%
Fair Value of Investments with Gross Unrealized Losses in loss position less than 12 months	$ 199.4	168.7
Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss	0.9
Available-for-sale Securities, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss		0.7
Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss	$ 2.2
Available-for-sale Securities, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss		$ 0.8

2. Fair Value Financial Instru

2. Fair Value Financial Instruments (Details) - USD ($) $ in Millions	Jun. 30, 2018	Dec. 31, 2017
Carrying (Reported) Amount, Fair Value Disclosure [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Other Investments		$ 91.8
Total long-term debt, excluding capital leases and current maturities	$ 423.4	423.1
Fair Value, Inputs, Level 2 [Member] | Estimate of Fair Value, Fair Value Disclosure [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Other Investments		1,249.4
Total long-term debt, excluding capital leases and current maturities	$ 439.4	$ 449.8

3. Intangible Assets, Goodwi39

3. Intangible Assets, Goodwill and Other (Details) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
	Mar. 31, 2018	Jun. 30, 2018	Dec. 31, 2017
Goodwill [Line Items]
Goodwill		$ 553,200	$ 559,300
Accumulated impairment loss		(53,200)	(53,200)
Goodwill, net		500,022	506,069
Goodwill, Written off Related to Sale of Business Unit		(1,400)
Currency fluctuations		(4,700)
Life Science [Member]
Goodwill [Line Items]
Goodwill		234,500	234,700
Accumulated impairment loss		(35,900)	(35,900)
Goodwill, net		198,600	198,800
Goodwill, Written off Related to Sale of Business Unit		0
Currency fluctuations		(200)
Clinical Diagnostics [Member]
Goodwill [Line Items]
Goodwill		318,700	324,600
Accumulated impairment loss		(17,300)	(17,300)
Goodwill, net		301,400	$ 307,300
Goodwill, Written off Related to Sale of Business Unit	$ (1,400)	(1,400)
Currency fluctuations		$ (4,500)

3. Intangible Assets, Goodwi40

3. Intangible Assets, Goodwill and Other Intangible Assets (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2017
Finite-Lived Intangible Assets, Net [Abstract]
Purchase Price	$ 501.9		$ 501.9		$ 509
Accumulated Amortization	(343.9)		(343.9)		(334.9)
Net Carrying Amount	158		158		174.1
Amortization [Abstract]
Amortization expense	7.4	$ 8.7	14.8	$ 15.6
Customer Relationships [Member]
Finite-Lived Intangible Assets, Net [Abstract]
Purchase Price	89.6		89.6		92.3
Accumulated Amortization	(65.7)		(65.7)		(64.4)
Net Carrying Amount	23.9		23.9		27.9
Know how [Member]
Finite-Lived Intangible Assets, Net [Abstract]
Purchase Price	192.3		192.3		194.9
Accumulated Amortization	(158.6)		(158.6)		(157.9)
Net Carrying Amount	33.7		33.7		37
Developed Technology Rights [Member]
Finite-Lived Intangible Assets, Net [Abstract]
Purchase Price	131.8		131.8		133.3
Accumulated Amortization	(74.2)		(74.2)		(70.3)
Net Carrying Amount	57.6		57.6		63
Licensing Agreements [Member]
Finite-Lived Intangible Assets, Net [Abstract]
Purchase Price	76.4		76.4		76.7
Accumulated Amortization	(38.5)		(38.5)		(36)
Net Carrying Amount	37.9		37.9		40.7
Trade Names [Member]
Finite-Lived Intangible Assets, Net [Abstract]
Purchase Price	3.9		3.9		3.9
Accumulated Amortization	(3.2)		(3.2)		(3)
Net Carrying Amount	0.7		0.7		0.9
Noncompete Agreements [Member]
Finite-Lived Intangible Assets, Net [Abstract]
Purchase Price	7.9		7.9		7.9
Accumulated Amortization	(3.7)		(3.7)		(3.3)
Net Carrying Amount	$ 4.2		$ 4.2		$ 4.6
Minimum [Member] | Customer Relationships [Member]
Finite-Lived Intangible Assets, Net [Abstract]
Average Remaining Life (years)			1 year	1 year
Minimum [Member] | Know how [Member]
Finite-Lived Intangible Assets, Net [Abstract]
Average Remaining Life (years)			1 year	1 year
Minimum [Member] | Developed Technology Rights [Member]
Finite-Lived Intangible Assets, Net [Abstract]
Average Remaining Life (years)			3 years	1 year
Minimum [Member] | Licensing Agreements [Member]
Finite-Lived Intangible Assets, Net [Abstract]
Average Remaining Life (years)			1 year	1 year
Minimum [Member] | Trade Names [Member]
Finite-Lived Intangible Assets, Net [Abstract]
Average Remaining Life (years)			3 years	1 year
Minimum [Member] | Noncompete Agreements [Member]
Finite-Lived Intangible Assets, Net [Abstract]
Average Remaining Life (years)			1 year	1 year
Minimum [Member] | Other Intangible Assets [Member]
Finite-Lived Intangible Assets, Net [Abstract]
Average Remaining Life (years)			0 years	0 years
Maximum [Member] | Customer Relationships [Member]
Finite-Lived Intangible Assets, Net [Abstract]
Average Remaining Life (years)			7 years	7 years
Maximum [Member] | Know how [Member]
Finite-Lived Intangible Assets, Net [Abstract]
Average Remaining Life (years)			8 years	8 years
Maximum [Member] | Developed Technology Rights [Member]
Finite-Lived Intangible Assets, Net [Abstract]
Average Remaining Life (years)			11 years	12 years
Maximum [Member] | Licensing Agreements [Member]
Finite-Lived Intangible Assets, Net [Abstract]
Average Remaining Life (years)			11 years	12 years
Maximum [Member] | Trade Names [Member]
Finite-Lived Intangible Assets, Net [Abstract]
Average Remaining Life (years)			6 years	6 years
Maximum [Member] | Noncompete Agreements [Member]
Finite-Lived Intangible Assets, Net [Abstract]
Average Remaining Life (years)			8 years	8 years
Maximum [Member] | Other Intangible Assets [Member]
Finite-Lived Intangible Assets, Net [Abstract]
Average Remaining Life (years)			0 years	0 years

4. Supplemental Cash Flow In41

4. Supplemental Cash Flow Information (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Supplemental Cash Flow Elements [Abstract]
Net Income (Loss) Attributable to Parent	$ 268,043	$ 5,035	$ 924,817	$ 17,448
Depreciation and Amortization			68,700	70,700
Share-based Compensation			12,100	10,600
Loss on Sale of Securities, Net			600	300
Changes in fair market value of equity securities			(1,102,300)	0
Gain on divestiture of a product line			(5,100)	0
Loss on Disposition of Property Plant Equipment			800	0
Gain on sale of land	$ 0	$ 0	(4,100)	0
Changes in fair value of contingent consideration			(2,400)	(8,700)
Decrease (increase) in accounts receivable			52,500	(1,800)
Increase in inventories			(11,700)	(37,900)
Increase in other current assets			(5,900)	(14,800)
Decrease in accounts payable and other current liabilities			(43,700)	(24,200)
Decrease in Income Taxes Payable			(20,900)	(13,200)
Increase (Decrease) in Deferred Income Taxes			246,200	(3,100)
Net increase in other long-term assets/liabilities			8,600	11,000
Net cash provided by operating activities			$ 118,208	$ 6,297

5. Long-Term Debt (Details)

5. Long-Term Debt (Details) - USD ($) $ in Thousands	3 Months Ended
	Jun. 30, 2018	Dec. 31, 2017	Dec. 31, 2010
Debt Instrument [Line Items]
Debt and Capital Lease Obligations	$ 440,500	$ 435,000
Less Current Maturities	(1,700)	(400)
Long-term debt, net of current maturities	438,776	434,581
Unsecured Debt [Member] | Senior Notes 4.875% due 2020 [Member]
Debt Instrument [Line Items]
Unsecured Debt	425,000	425,000
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net	$ 1,600	1,900
Debt Instrument, Interest Rate, Stated Percentage			4.875%
Debt Instrument, Redemption Price, Percentage	100.00%
Long-term debt	$ 423,400	423,100	$ 422,600
Debt Instrument, Interest Rate, Effective Percentage			4.946%
Face amount of debt sold			$ 425,000
Capital Lease Obligations [Member] | Capital Leases and Other Debt [Member]
Debt Instrument [Line Items]
Long-term Debt and Capital Lease Obligations, Including Current Maturities	17,100	$ 11,900
Line of Credit [Member]
Debt Instrument [Line Items]
Line of credit maximum borrowing capacity	200,000
Outstanding borrowings	$ 0
Line of Credit Facility, Interest Rate at Period End	3.46%
Standby Letters of Credit [Member]
Debt Instrument [Line Items]
Line of credit maximum borrowing capacity	$ 500

6. Accumulated Other Compreh43

6. Accumulated Other Comprehensive Income 6. Accumulated Other Comprehensive Income (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning balance, Accumulated other comprehensive income			$ 738,794
Total other comprehensive income (loss) net of tax	$ (122,795)	$ 94,305	(78,247)	$ 193,182
Ending balance, Accumulated other comprehensive income	(18,710)		(18,710)
Accumulated Translation Adjustment [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning balance, Accumulated other comprehensive income			77,400	1,300
Other Comprehensive Income (Loss), before Reclassifications, before Tax			(77,600)	60,500
Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax			0	0
Other Comprehensive Income (Loss), Tax			0	0
Total other comprehensive income (loss) net of tax			(77,600)	60,500
Ending balance, Accumulated other comprehensive income	(200)	61,800	(200)	61,800
Accumulated Defined Benefit Plans Adjustment [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning balance, Accumulated other comprehensive income			(22,300)	(18,600)
Other Comprehensive Income (Loss), before Reclassifications, before Tax			500	(2,500)
Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax			800	0
Other Comprehensive Income (Loss), Tax			(100)	500
Total other comprehensive income (loss) net of tax			1,200	(2,000)
Ending balance, Accumulated other comprehensive income	(21,100)	(20,600)	(21,100)	(20,600)
Accumulated Defined Benefit Plans Adjustment [Member] | Reclassification Out Of Accumulated Other Comprehensive Income [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Other (income) expense, net	(500)	200	(800)	0
Accumulated Net Unrealized Investment Gain (Loss) [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning balance, Accumulated other comprehensive income			4,500	435,000
Other Comprehensive Income (Loss), before Reclassifications, before Tax			(2,100)	213,200
Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax			200	0
Other Comprehensive Income (Loss), Tax			0	(78,500)
Total other comprehensive income (loss) net of tax			(1,900)	134,700
Ending balance, Accumulated other comprehensive income	2,600	569,700	2,600	569,700
Accumulated Net Unrealized Investment Gain (Loss) [Member] | Reclassification Out Of Accumulated Other Comprehensive Income [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Other (income) expense, net	100	200	200	0
Parent [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning balance, Accumulated other comprehensive income			59,600	417,700
Other Comprehensive Income (Loss), before Reclassifications, before Tax			(79,200)	271,200
Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax			1,000	0
Other Comprehensive Income (Loss), Tax			(100)	(78,000)
Total other comprehensive income (loss) net of tax			(78,300)	193,200
Ending balance, Accumulated other comprehensive income	$ (18,700)	$ 610,900	$ (18,700)	$ 610,900

7. Earnings Per Share (Details

7. Earnings Per Share (Details) - shares shares in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Basic weighted average shares outstanding	29,814	29,613	29,801	29,597
Effect of potentially dilutive stock options and restricted stock awards	405	393	396	365
Diluted weighted average common shares	30,219	30,006	30,197	29,962
Anti-dilutive shares	13	0	13	15

8. Other Income and Expenses45

8. Other Income and Expenses (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Interest and investment income	$ (16,200)	$ (12,000)	$ (18,300)	$ (13,100)
Net realized loss (gain) on investments	100	200	200	(100)
Gain on sale of land	0	0	(4,100)	0
Gain on divestiture of a product line	0	0	(5,100)	0
Other Nonoperating Expense	200	400	300	800
Nonoperating Income (Expense)	$ (15,858)	$ (11,382)	$ (27,003)	$ (12,425)

9. Income Taxes (Details)

9. Income Taxes (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2017	Jan. 01, 2018
Effective tax rate	21.00%	(350.00%)	23.00%	18.00%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent			21.00%
Tax Cuts and Jobs Act, Incomplete Accounting, Provisional Income Tax Expense (Benefit)					$ 55
Significant Change in Unrecognized Tax Benefits is Reasonably Possible, Amount of Unrecorded Benefit	$ 3		$ 3
U.S. Federal [Member]
Statutory Rates				35.00%
Adjustments for New Accounting Pronouncement [Member]
Deferred Income Tax Assets, Net						$ 232.9
Deferred Income Tax Expense (Benefit)	$ 62.6		$ 243.8

10. Segment Information (Detai

10. Segment Information (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Segment Reporting Information [Line Items]
Net sales	$ 575,911	$ 504,666	$ 1,127,430	$ 1,004,717
Income before income taxes	340,086	1,120	1,203,775	21,267
Life Science [Member]
Segment Reporting Information [Line Items]
Net sales	217,800	179,400	415,600	353,600
Income before income taxes	12,200	(22,900)	15,500	(41,700)
Clinical Diagnostics [Member]
Segment Reporting Information [Line Items]
Net sales	354,000	322,100	704,800	644,400
Income before income taxes	27,800	18,500	64,400	60,100
All Other Segments [Member]
Segment Reporting Information [Line Items]
Net sales	4,100	3,200	7,000	6,700
Income before income taxes	$ 0	$ 200	$ 0	$ 400

10. Segment Profit Reconciliat

10. Segment Profit Reconciliation (Details) - USD ($) $ in Thousands	3 Months Ended			6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Mar. 31, 2017	Jun. 30, 2018	Jun. 30, 2017
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Income before income taxes	$ 340,086	$ 1,120		$ 1,203,775	$ 21,267
Unrealized Gain on Securities	286,398	0		1,102,332	0
Operating Segments [Member]
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Income before income taxes	40,000	(4,200)		79,900	18,800
Corporate, Non-Segment [Member]
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Income before income taxes	(2,200)	(3,600)		(4,200)	(5,600)
Segment Reconciling Items [Member]
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Unrealized Gain on Securities	286,400	0		1,102,300	0
Foreign Currency Gain (Loss) [Member] | Segment Reconciling Items [Member]
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Income before income taxes	0	(2,500)		(1,200)	(4,300)
Other Nonoperating Income (Expense) [Member] | Segment Reconciling Items [Member]
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Income before income taxes	15,900	11,400		27,000	12,400
Life Science [Member]
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Business Combination, Separately Recognized Transactions, Additional Disclosures, Acquisition Cost Expensed			$ 10,000
Income before income taxes	12,200	(22,900)		15,500	(41,700)
Clinical Diagnostics [Member]
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Research and Development Asset Acquired Other than Through Business Combination, Written-off		7,500
Income before income taxes	$ 27,800	$ 18,500		$ 64,400	$ 60,100

11. Legal Proceedings 11. Cont

11. Legal Proceedings 11. Contingent Liability (Details)	12 Months Ended
	Dec. 31, 2017USD ($)
Legal Proceedings [Abstract]
Loss Contingency, Damages Awarded, Value	$ 10,920,000
Litigation Settlement Interest	$ 141,608

12. Restructuring Costs (Detail

12. Restructuring Costs (Details) - USD ($) $ in Millions	3 Months Ended	6 Months Ended	7 Months Ended	26 Months Ended
	Jun. 30, 2018	Jun. 30, 2018	Jun. 30, 2018	Jun. 30, 2018	Dec. 31, 2017
European Reorganization [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve	$ 4.2	$ 4.2	$ 4.2	$ 4.2	$ 6.3
Restructuring Charges		0		12.9
Restructuring Reserve, Current	4.1	4.1	4.1	4.1
Restructuring Reserve, Noncurrent	0.1	0.1	0.1	0.1
Restructuring Reserve, Accrual Adjustment		(0.1)
Payments for Restructuring		(1.9)
Restructuring Reserve, Foreign Currency Translation (Gain) Loss		(0.1)
European Reorganization [Member] | Cost of Goods, Total [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve, Accrual Adjustment		(0.1)
European Reorganization [Member] | Selling, General and Administrative Expenses [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve, Accrual Adjustment		(0.1)
European Reorganization [Member] | Life Science [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve	1.6	1.6	1.6	1.6	2.2
Restructuring Charges		0
Restructuring Reserve, Accrual Adjustment		0
Payments for Restructuring		(0.6)
Restructuring Reserve, Foreign Currency Translation (Gain) Loss		0
European Reorganization [Member] | Clinical Diagnostics [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve	2.6	2.6	2.6	2.6	4.1
Restructuring Charges		0
Restructuring Reserve, Accrual Adjustment		(0.1)
Payments for Restructuring		(1.3)
Restructuring Reserve, Foreign Currency Translation (Gain) Loss		(0.1)
Termination of a Diagnostics Research and Development Project [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Charges			20.4
Restructuring Reserve, Accrual Adjustment	(0.6)	(0.7)
Facility Closing [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Charges		1.3
Termination of a Diagnostics Research and Development Project and a Facility Closure [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve	11.7	11.7	11.7	11.7	$ 14.1
Restructuring Charges		1.3
Restructuring Reserve, Accrual Adjustment		(0.7)
Payments for Restructuring		(2.7)
Restructuring Reserve, Foreign Currency Translation (Gain) Loss		(0.3)
Termination of a Diagnostics Research and Development Project and a Facility Closure [Member] | Cost of Goods, Total [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Charges	1.3	1.3
Termination of a Diagnostics Research and Development Project and a Facility Closure [Member] | Selling, General and Administrative Expenses [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve, Accrual Adjustment	(0.3)	(0.1)
Termination of a Diagnostics Research and Development Project and a Facility Closure [Member] | Research and Development Expense [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve, Accrual Adjustment	(0.3)	(0.6)
Termination of a Diagnostics Research and Development Project and a Facility Closure [Member] | Accounts Payable and Accrued Liabilities [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve, Current	7.2	7.2	7.2	7.2
Termination of a Diagnostics Research and Development Project and a Facility Closure [Member] | Other Current Liabilities [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve, Current	3.2	3.2	3.2	3.2
Termination of a Diagnostics Research and Development Project and a Facility Closure [Member] | Other Noncurrent Liabilities [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve, Noncurrent	$ 1.3	$ 1.3	$ 1.3	$ 1.3